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Tight junction modulatorlial barriers of the human body are major obstacles for drug delivery to the
systemic circulation and to organs with unique environment and homeostasis, like the central nervous
system. Several transport routes exist in these barriers, which potentially can be exploited for enhancing drug
permeability. Beside the transcellular pathways via transporters, adsorptive and receptor-mediated
transcytosis, the paracellular ﬂux for cells and molecules is very limited. While lipophilic molecules can
diffuse across the cellular plasma membranes, the junctional complexes restrict or completely block the free
passage of hydrophilic molecules through the paracellular clefts. Absorption or permeability enhancers
developed in the last 40 years for modifying intercellular junctions and paracellular permeability have
unspeciﬁc mode of action and the effective and toxic doses are very close. Recent advances in barrier research
led to the discovery of an increasing number of integral membrane, adaptor, regulator and signalling proteins
in tight and adherens junctions. New tight junction modulators are under development, which can directly
target tight or adherens junction proteins, the signalling pathways regulating junctional function, or tight
junction associated lipid raft microdomains. Modulators acting directly on tight junctions include peptides
derived from zonula occludens toxin, or Clostridium perfringens enterotoxin, peptides selected by phage
display that bind to integral membrane tight junction proteins, and lipid modulators. They can reversibly
increase paracellular transport and drug delivery with less toxicity than previous absorption enhancers, and
have a potential to be used as pharmaceutical excipients to improve drug delivery across epithelial barriers
and the blood–brain barrier.
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Epithelial and endothelial barriers separate the organisms from the
external environment and the body compartments from each other.
The tight intercellular seals responsible for the effective separation
were identiﬁed as zonula occludens or tight junctions (TJ) by electron
microscopy more than 50 years ago (for review see [1]). In the last
25 years the discovery of the transmembrane proteins of TJs [2] and
the signalling pathways regulating TJ functions [3] resulted in a great
advance in understanding how epithelial and endothelial barriers
work and how this knowledge can be exploited in disease therapies,
drug discovery and drug targeting.
The non-invasive delivery of hydrophilic drugs or large biophar-
maceuticals to the systemic circulation or to speciﬁc organs
protected by a barrier, like the central nervous system (CNS), is
still a big challenge. Drug absorption or penetration across epithelial
and endothelial barriers is restricted by several factors. Efﬂux
transporters expressed at high levels in epithelia [4] and the
blood–brain barrier (BBB) [5] prevent not only the ﬂux of
xenobiotics, but also drug molecules to reach their target. Local
metabolic barriers act as a second line of defence and speciﬁc
enzymes are able to inactivate drugs, cleave proteins and peptides, or
other biologically active compounds [6]. The third major cause is the
presence of intercellular TJs that strictly limit the paracellular route.
In the last 50 years several methods, molecules, and excipients have
been investigated for the safe and reversible opening of these
junctions to enhance drug absorption and penetration. Low efﬁcacy
and high toxicity prevented these approaches to be useful for
pharmaceutical therapy. New TJ modulators, designed to interact
directly with TJ proteins or regulating molecules, are promising
candidates to improve drug delivery.2. Major epithelial and endothelial barriers and drug delivery
The paracellular permeability, one of the most important determi-
nants of drug transport, of various epithelial tissues and barriers
differs greatly [7]. Transepithelial electrical resistance (TEER), mea-
suring paracellular ion ﬂux and reﬂecting the tightness of the
intercellular junctional complex, is the lowest in the small intestine,
which is considered as a leaky epithelial tissue. The TJs in the colon
and the stomach are of intermediate tightness, while brain capillaries
and the skin epithelial cells form very tight paracellular barriers.
2.1. Epithelial barriers of the gastrointestinal tract
Oral administration of drugs is the most popular and widespread
method of drug therapy. The patients' compliance is high, because it is
safe, efﬁcient, easily accessible and causes minimal discomfort.
Membrane permeability is one of the major factors which determine
drug absorption after oral administration. The total surface area of the
intestine is approximately 200 m2. Except for the buccal and rectal
mucosa, where the surface consists of stratiﬁed squamous epithelium,
a columnar epithelial cell layer covers the surface in the other parts of
the gastrointestinal (GI) tract. The lower parts of the small intestine,
jejunum and ileum, are considered as the major place of drug
absorption, because of the leaky paracellular tight junctions reﬂected
by the low transepithelial electrical resistance, as compared to the
other parts of the GI tract [7]. The villous structure of the jejunum and
ileum ampliﬁes the surface area four and two-folds, respectively, as
compared to the colon [8], another factor in drug absorbance.
Although the gastric epithelium is much tighter than the small
intestine [7], gastric absorption can be substantial for drugs
administered in rapidly dissolving formulations or for lipophilic
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between the regions of the GI tract [8] are caused by the dissimilar
anatomical structures, distinct lipid composition of the plasma
membranes and expression of diverse members of the claudin TJ
protein family [2].
The paracellular permeability pathway in the buccal and rectal
mucosa is restricted, and their surface area is small (approx. 100–
200 cm2), nevertheless they are important drug delivery sites. Due to
their special anatomical location the blood from their submucosa is
directly drained toward the superior or inferior vena cava, respec-
tively, avoiding ﬁrst pass metabolism in the liver and intestine, which
is important for a fast effect in crisis therapy (e.g. anti-angina
treatment, anticonvulsants, analgesics, antipyretics).
2.2. Airway epithelium
Drug delivery across pulmonary epithelia, ciliated epithelial cells,
type I and type II pneumocytes, is an attractive route for non-invasive
local and systemic therapy [9]. The alveolar surface area is large, about
160 m2, close to the surface area of the GI tract. Pulmonary drug
delivery systems for macromolecules, peptides and proteins, like
insulin, antibodies and vaccines have been developed and their
applications have a great therapeutical potential [9]. Exubera, the ﬁrst
inhaled insulinwas approved for clinical use in Europe and the United
States, but marketing was stopped in 2007.
2.3. Skin
From all of the epithelial barriers the skin is the least permeable to
molecules due to its special anatomical and molecular structure. The
stratum corneum, the outermost layer composed of keratin-ﬁlled
corneocytes in a special lipid matrix, is responsible for the extremely
low permeability to water and solutes. Despite the fact, that skin
represents a major barrier to drug transport, transdermal drug
delivery is the most successful non-oral technology for systemic
drug delivery in the pharmaceutical market [10]. Transdermal systems
offer a non-invasive, slow, sustained drug delivery across an accessible
and relatively large, 1–2 m2 surface area [10].
2.4. Blood–brain barrier
The BBB, a dynamic interface separating the brain from systemic
circulation, is the major entry route for therapeutical compounds to
the CNS. The estimated total length of human brain capillaries is
650 km, with a total surface area of 10 to 20m2 [11]. The complex tight
junctions between brain endothelial cells constitute the morphologi-
cal basis of the BBB [12]. The primary role of the BBB is to create ionic
homeostasis for neuronal functions [13]. It also provides the CNS with
nutrients and protects it from toxic insults by sophisticated transport
systems [5]. The low level of paracellular ﬂux and transendothelial
vesicular trafﬁcking result in a transport barrier for drugs which are
hydrophilic and have a molecular mass bigger than 400 Da, while the
presence of effective efﬂux transporters at the luminal membrane of
brain endothelial cells limits the brain penetration of lipophil
xenobiotics and drugs. The BBB prevents 98% of potential neurophar-
maceuticals, especially the new peptide or protein drugs, to reach
their targets in the CNS [14]. Due to these reasons the treatment of
CNS diseases, including stroke, Alzheimer's disease, and brain
tumours, is still unsatisfactory and improving drug delivery to the
CNS is considered essential for the future success of the therapy of
neurological disorders [15].
2.5. Alternative routes for drug delivery
Besides conventional local treatments, the nasal route can be also
exploited for systemic, non-invasive delivery of drugs [16]. The nasalepithelial surface area is small, about 150 cm2, and consists of
respiratory and olfactory regions. Although the olfactory system
possesses elaborate epithelial, endothelial and glial barriers expressing
occludin, claudins and other TJ proteins [17], due to its special
anatomical localization it provides a direct access to the CNS by
circumventing the BBB [18]. Another advantage of the nasal delivery is
the rapid onset of action, which makes this route suitable for crisis
treatments. An increasing number of nasal formulations are used
clinically for the treatment of migraine [16].
A new alternative route to brain across the epithelial barriers of the
eye emerges, which also bypasses the BBB. Recent experimental
results indicate the possibility of drug delivery to the CNS following
ocular application through non-systemic routes [19,20].
3. Potential targets of TJ modulators
Tight junctions, sealing the paracellular clefts between cells of the
epithelial and endothelial barriers in mammals are elaborate
structures composed of integral membrane proteins (for reviews see
[2,21]), linker or adaptor proteins connecting them to the actin
cytoskeleton [22] and signalling molecules enabling the dynamic
regulation of the paracellular transport [3]. Adherens junctions (AJ)
are also present in both types of barriers, however differences in their
localization, morphology, and molecular composition exist. While in
brain endothelial cells tight and adherens junctions are intermingled
[23], in epithelial barriers AJs are situated in the apical junctional
complex in basolateral direction from the TJs. Some of the junctional
proteins are found in raft-like membrane microdomains in epithelial
cells [24]. These compartments can play an important role in the
spatial organization of TJs and probably in the regulation of epithelial
paracellular permeability. Theoretically all these components listed
above can be considered as potential targets of TJ modulators (Fig. 1).
Some of the junctional proteins seem to be excellent targets for safe
modulation of paracellular permeability, while targeting other
adhesion molecules playing a fundamental role in morphogenesis
should be considered cautiously, e.g. where loss of function is strongly
linked to carcinogenesis.
3.1. Transmembrane TJ proteins
Occludin, the ﬁrst integral membrane TJ protein, was supposed to
contribute to both the gate and fence functions [25]. Experiments with
occludin-deﬁcient cells and animals revealed morphologically unaf-
fected TJs and no barrier dysfunction [2]. However, chronic inﬂamma-
tion and hyperplasia of the gastric epithelium, calciﬁcation in the
brain, testicular atrophy and other histological abnormalities in the
salivary gland and in the bones were observed in occludin deﬁcient
mice [26] suggesting more complex functions of occludin. Occludin
internalization by caveolar endocytosis was found to be linked to
barrier dysfunction in intestinal inﬂammation (for review see [27]).
From the accumulated data a new role for occludin as a signal
transmitter in TJs regulating development, apoptosis in healthy and
cancer cells, and actin cytoskeleton emerges [2].
Tricellulin, a recently discovered TJ protein showing partial
homology with occludin, is expressed uniquely at tricellular contacts
of epithelial cells [28]. It also participates in the barrier function and
organization of bicellular junctions. Interestingly, the only described
phenotype of tricellulin gene mutation is deafness, due to the loss of
the protein from tricellular junctions in cochlear and vestibular
epithelial cells [29].
Claudins form a large gene family with 24 members identiﬁed so
far, which are able to determine the tissue-, charge- and size-
selectivity of the paracellular seals [2,21]. Data from different claudin
null mutant mice strains and transfection experiments indicate that
claudin-1, -3, -4, -5, -8, -11, -14 and -19 contribute to the tightness of
paracellular barriers [21]. Claudins are key elements in the loss of
Fig. 1. Schematic model of targets of tight junction modulators in epithelial and endothelial cells. Abbreviations: 7H6, cytoplasmic tight junction-associated protein; AJ, adherens
junction; CASK, Ca2+-dependent serine protein kinase; ESAM, endothelial selective adhesion molecule; GEF-H1, Guanine nucleotide exchange factor H1; Itch, E3 ubiquitin protein
ligase; JAMs, junctional adhesion molecules; MAGI 1-3, membrane-associated guanylate guanylate kinase with inverted orientation of protein-protein interaction domains; MAPK,
mitogen-activated protein kinase; MLCK, myosin light chain kinase; MUPP 1, multi-PDZ-protein 1; PAR3/6, partitioning defective proteins 3 and 6; PECAM, platelet-endothelial cell
adhesionmolecule; PI3K/Akt, phosphoinositide 3-kinase/Akt pathway; PKA, protein kinase A; PKC, protein kinase C; PKG, protein kinase G; RGS5, regulator of G-protein signalling 5;
Rho/ROCK, Rho/Rho-associated protein kinase pathway; TJ, tight junction; ZO-1, zonula occludens 1; ZO-2, zonula occludens 2; ZO-3, zonula occludens 3; ZONAB, ZO-1-associated
nucleic acid-binding protein.
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review see [30]).
The paracellular ion permeability through TJs is regulated by both
sealing and pore forming claudins. Claudin-4, -8, and -14 function
primarily in cation barriers, while other members of the claudin
family, claudin-2, -7, -10, -13, -15, -16, form paracellular pores for
cations or anions [2]. They also participate in magnesium and calcium
reabsorption, as revealed by the mutation of the human claudin-16
and 19 genes [31,32]. In MDCK mammalian renal epithelial cells tight
junction leakiness is conferred by expression of claudin-2 [33].
The differential expression of claudins in tissues and cell types
provide the basis for the large spectrum of the paracellular tightness
of the junctional complexes in various organs [2]. The epidermal
barrier is disrupted in claudin-1 deﬁcient mice [34], and claudin-11
plays a role in the blood–testis barrier [35]. In the GI tract claudin-2,
-3, -4, -7, -8, -12 and -15 are all expressed, but the level of their
expression in various intestinal segments and their subcellular
localization are different [2]. Their role in the structural organization
of the intestinal barrier is emphasized by a recent ﬁnding. Claudin-15
deﬁcient mice show a megaintestine phenotype, the upper part of the
small intestine is two times larger than normal in length and diameter
[36].
The presence of claudin-1, -3, -5, -12 and -18 were described in
brain endothelial cells [21]. A special regulatory role for claudin-5,
expressed in endothelial but not in epithelial cells, was discovered in a
knock-out mice. Tracer experiments and magnetic resonance imaging
revealed that in the absence of claudin-5 the BBB permeability was
selectively increased for small molecules (b800 Da), but not for larger
molecules [37].
Junctional adhesion molecules (JAMs), another family of integral
membrane proteins in TJs, are involved in intercellular adhesion
between the cells of barriers, as well as in adhesion between barriers
and blood cells [2,22]. JAM-A, expressed in both epithelial and
endothelial cells, and coxsackie and adenovirus receptor (CAR)expressed only in epithelial cells, contribute to barrier function and
cell polarity in epithelial and endothelial cells, while JAM-B and -C
participates in spermatogenesis [2]. In addition, JAM-A and JAM-C
control transmigration of neutrophils and monocytes across endothe-
lial and epithelial cells, another important aspect of barrier functions.
Endothelial cell-selective adhesion molecule (ESAM) is expressed in
vascular endothelial cells, where it colocalizes with cadherins and
catenins in junctions [38]. ESAM is present at the BBB and it is
enriched in the BBB genome [39]. Loss of ESAM alters angiogenesis in
pathological conditions, reduces extravasation of neutrophil leuko-
cytes and vascular endothelial growth factor (VEGF)-induced perme-
ability in vessels [40].
Integral membrane TJ proteins also serve as receptors for
pathogenic bacteria and viruses, and they can be the targets of
bacterial toxins (for review see [41]). Claudin-1 is a co-receptor for
hepatitis virus C, and claudin-4 is a receptor for Clostridium perfringens
enterotoxin (CPE), while JAM-A binds reoviruses, and coxsackie and
adenoviruses target CAR [2]. CPE served as a model sequence for the
design of new, highly speciﬁc TJ modulator peptides [42,43].
3.2. Transmembrane adherens junction proteins as targets of
paracellular barrier modulators
AJs, present in both epithelial and endothelial barriers initiate and
stabilize cell–cell contacts and help the formation of TJs [44]. AJ
proteins also participate in the regulation of barrier permeability.
Similarly to JAMs, the calcium-dependent adhesion molecules,
cadherins also belong to the immunoglobulin superfamily. E-cadherin
is present in all epithelial barriers, and its presence was also
demonstrated in brain endothelial cells [45]. E-cadherin is important
for establishing andmaintaining apico-basal polarity as well as for the
formation of TJs [46]. Loss of E-cadherin in the epidermis, by
conditionally inactivating its gene in mice, results in perinatal death
due to the inability to retain a functional epidermal water barrier [47].
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tion of claudin-1, -4 and ZO-1 at TJs through activation of Rac, a small
GTPase of the Rho family, and protein kinase C (PKC) [47]. Histamine
increases airway epithelial cell permeability by decreasing E-
cadherin-based epithelial cell adhesion [48]. E-cadherin plays a
basic role in morphogenesis. Embryonic stem cells isolated from E-
cadherin−/− preimplantation embryos fail to differentiate into any
organized structurewhen induced to form teratomas in mice [46]. The
loss or down-regulation of E-cadherin is a key event in the process of
cancer invasion and metastasis [49]. Mutations in CDH1 that
compromise the adhesive function of E-cadherin have been observed
in human gastric carcinoma cell lines, lobular breast cancer, and
familial gastric cancer [49].
Vascular endothelial, or VE-cadherin, another member of the large
cell adhesion molecule cadherin family, is highly and uniquely
expressed in the endothelium of all types of vessels [50]. VE-cadherin
is indispensable for the developmental organization of the vascula-
ture, and its inactivation or truncation leads to an embryonic lethal
phenotype [50]. Vasoactive and proinﬂammatory mediators disrupt
endothelial adherens junctions, especially the association of VE-
cadherin with the cytoplasmic linker molecules catenins resulting in
an increase in vascular permeability [51]. It has been recently
identiﬁed, that VEGF controls endothelial-cell permeability by
promoting the beta-arrestin-dependent endocytosis of VE-cadherin
[52].
The nectins form another important family of adhesion molecules
in AJs [53]. These immunoglobulin-like cell adhesion molecules
provide the ﬁrst scaffold for AJ and TJ formation. Nectins-1, -2, -3
are expressed in epithelial, endothelial, hematopoietic and neuronal
cells in adult tissues, while nectin-4 is mainly expressed during
embryogenesis [54]. Nectin-4 has been identiﬁed as a new histological
and serological tumour associated marker for breast cancer [55].
Platelet-endothelial cell adhesion molecule-1 (PECAM-1) is pre-
sent in endothelial and blood cells, but absent in epithelial barriers
[50]. It participates in the formation of endothelial junctions and in the
transmigration of leukocytes across endothelium [56]. Effective
treatment of gut barrier dysfunction was achieved using monoclonal
antibodies against PECAM-1 [57]. A new role for PECAM-1 is suggested
at the BBB. By counteracting intercellular adhesionmolecule-1 (ICAM-
1)-induced activation in brain endothelial cells it can limit rearrange-
ments of the actin cytoskeleton and maintain the integrity of brain
vascular endothelium [58].
Similarly to transmembrane TJ proteins, some of the AJ proteins
can bind infectious agents. E-adherin, transiently exposed at sites of
cell extrusion, is a speciﬁc target of Listeria monocytogenes adhesion
and invasion by binding Internalin A, bacterial cell surface protein
[59]. Nectin-1 is a cell-surface receptor for herpes simplex virus type 1
envelope glycoprotein D, and it is used for targeting attenuated,
oncolytic herpes simplex virus to infect and lyse human malignancies
in preclinical studies [60].
3.3. Signalling pathways regulating TJ functions
The dynamic changes at the junctions, disintegration and
reassembly of TJs, reversible changes in paracellular permeability,
are regulated by signalling pathways in epithelial barriers and the BBB
(for reviews see [3,61,62]). Themajor signalling routes that participate
in TJ opening with a potential to be exploited for drug delivery involve
protein kinases A, C and G (PKA, PKC, PKG), Rho kinases, myosin light
chain kinase (MLCK), and the mitogen activated protein kinase
(MAPK) system (Fig. 1) [3,61,62]. The effects of certain pathways
greatly differ between tissues, cell types, and models, so it is difﬁcult
to draw general conclusions.
Conventional PKC isoforms (α, β II) participate in TJ opening or
disassembly [61]. A wide range of pathological and physiological
signals acts through PKC, like removal of extracellular Ca2+, elevationof intracellular Ca2+ levels by phorbol esters or Ca2+ ionophore
A23187 [3,62]. Ca2+ chelators, used as absorption enhancers (AE) at
different barriers also activate PKC. Pathological stimuli, like oxidative
stress, cytokines (tumour necrosis factor-α (TNF-α), etc.), and
vascular endothelial growth factor (VEGF), as well as toxins from
infectious agents, HIV-1 gp120, Vibrio cholerae zonula occludens toxin
(Zot), Clostridium difﬁcile toxin A, Escherichia coli OmpA all use PKC
signalling to open tight junctions [3]. Bryostatin 1, a novel anticancer
agent and a non-phorbol ester stimulator of PKC transiently increases
TJ permeability in epithelial cells through rapid downregulation of
PKC-α [63].
While the role of PKA is controversial in TJ regulation in epithelial
barriers, it is linked to barrier tightening in brain endothelial cells
[3,62]. Elevation of intracellular cyclic AMP by cyclic-AMP analogues
[64], phosphodiesterase 4 inhibitors, or by physiological regulators,
like the peptide hormone adrenomedullin [65] results in increased
TEER and decreased paracellular permeability [62,66] through
enhanced expression of claudin-5 at TJs [67]. Inhibitors of this
pathway could increase the paracellular permeability at the BBB.
In contrast, PKG mediates BBB opening via soluble guanylate
cyclase activation and elevation of cyclic GMP [3,62,66]. The
bradykinin B2 receptor agonist Cereport acting through this pathway
could effectively and reversibly open brain endothelial TJs [68].
Pathological conditions, like hypoxia, ischemia or excessive nitric
oxide (NO) release, either endogenous, or from NO-donors, also
activate soluble guanylate cyclase and PKG and increase BBB perme-
ability [62,66].
One of the main effector mechanisms in TJ regulation is the
phosphorylation of myosin light chain (MLC) by MLCK leading to the
contraction of the acto-myosin belt and disassembly of TJs [61].
Cytokines, bacterial or viral pathogens, removal of extracellular Ca2+,
as well as bile acids, used as absorption enhancers (AEs), trigger TJ
opening via MLCK activation [3]. The vasoactive mediator histamine
and the lysophosphatidic acid (LPA) also compromise the integrity of
brain endothelial cells by MLCK activation [69].
Mitogen activated protein kinases (MAPKs) modulate paracellular
permeability of TJs by regulating the expression of several TJ proteins
(for review see [3,61]). Three of the four groups of MAPKs,
extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase
(JNK) and p38 isoforms participate in regulation of the barrier
function. Ethanol-induced decrease in the barrier function uses all
three pathways, while proinﬂammatory cytokines can induce both
Erk1/2 and p38 MAPKs. Bile salts, reactive oxygen species (ROS),
pathogenic factors of viruses and bacteria activate predominantly the
Erk1/2 via Ras and Raf [3]. While all the above mentioned pathways
result in a decrease in the paracellular barrier function, activation of
Erk1/2 signalling pathway by negatively controlling claudin-2
expression can also enhance paracellular tightness in MDCK renal
epithelial cells [33]. In contrast, Erk1/2 inhibiton by inducing claudin-
2 expression in renal epithelial cells leads to a decreased TEER [33],
which is in agreement with the role of claudin-2 known to be able to
form paracellular pores for cations and anions [2]. This observation
indicates that regulation of paracellular barrier tightness, at least for
ions, can be achieved by alteration in claudin composition within TJ
complexes. Furthermore, the polymerization of claudins is critically
dependent on binding to TJ membrane-associated guanylate guany-
late kinase proteins ZO-1, ZO-2 and ZO-3. In Eph4 mouse epithelial
cells with no expression of ZO proteins a complete lack of TJs could be
observed [70].
Activation of RhoA, Rac1 and Cdc42, members of the Rho family of
GTPases, all disrupt epithelial tight junctions [71]. RhoA interacts with
the PKC and MLCK pathways and regulates TJ disassembly through
phosphorylation of integral membrane TJ proteins occludin and
claudin-5 and scaffolding proteins ZO-1 and ZO-2 [3]. The level of
RhoA is critical for TJ regulation, and either inactivation of it by C3
transferase, a speciﬁc inhibitor, or activation by cytokine interferon-γ
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disassembly [3]. RhoA participates in reduced brain endothelial TJ
functions after LPA treatment [69], and in ROS-induced alterations in
BBB integrity and monocyte migration across brain endothelial cells
[72].
The activation of phosphoinositide 3-kinases (PI3Ks) can induce
both tightening and opening of TJs depending on the inducing agent
and barrier type [61]. While the PI3K/Akt pathway participates in the
restitution of injured barrier in intestinal epithelium [73], the same
PI3-K/Akt signalling route is responsible for hyperpermeability
induced by ROS [72,74], placenta-derived growth factor, VEGF [75],
HIV gp120 [76] and HIV Tat [77] in BBB models.
3.4. Lipid rafts and membrane microdomains
It is known for a long time, that lipids are involved in the formation
and regulation of TJs and lipid models of the TJs have been suggested
to explain lipid exchange between the apical membranes of
neighbouring the cells, i.e. the “bridge” function of cell–cell adhesions
(Fig. 1) [78]. TJs are enriched in cholesterol [79] and alterations in cell
cholesterol modulate junctional permeability for ions [80]. TJ proteins
occludin, claudin-1, -3, -4, -7, JAM-A and ZO-1 have been shown to be
associated with detergent insoluble glycolipid raft structures rich in
caveolin-1 [24,81]. TJ disassembly by calcium chelation resulted in
displacement of TJ proteins from the lipid rafts suggesting an
important role for these structures in regulation of paracellular
permeability [24]. Data indicate that alteration in lipid composition of
epithelial cell membrane, especially cholesterol efﬂux, can result in TJ
modulation [81,82]. Depletion of cholesterol from Caco2 epithelialTable 1
Targets and mode of action of modulators directly acting on tight junction components
Target molecule Mechan
Modulators acting on tight junction proteins
Occludin
Occludin EC loop
EC loop
EC loop
Ligand-f
Peptide
Cleavage
Gene ex
Gene ex
Claudins
Claudin-4 CPE rece
Claudin-4 Gene ex
Claudins 1–10 Peptide
Claudin-23 EC loop
Junctional adhesion molecules
JAMs 1–3 peptide analogues 425 contiguous amino acid peptides [91] Peptide
JAM-1 Gene ex
Modulators acting on adherens junction proteins
E-cadherin
E-cadherin EC1 dom
EC1 dom
Modulators acting on signalling pathways regulating tight junctions
Zot receptor PKC-α a
Zot receptor PKC-α a
Zot receptor PKC-α a
Zot receptor PKC-α a
Modulators acting on lipid rafts and membranes
Lipid rafts TJ/AJ di
Modulators acting on miscellaneous targets
[Not disclosed] Peptide
TJ GAGs GAG-de
Abbreviations: AJ, adherens junction; CPE, Clostridium perfringens enterotoxin; EC, extracellula
molecule; OP90–103, occludin peptide 90–103; PGPC, 1-palmitoyl-2-glutaroyl-sn-glycero-3-ph
junction; Zot, zonula occludens toxin.cells by methyl-β-cyclodextrin, used as AE, results in loss of TJ
integrity and displacement of occludin, claudin-3, -4, -7 and JAM-A
out of the cholesterol rich membrane domains [81]. Lipid mediators
and secondmessengers activating signalling pathways that regulate TJ
permeability can mediate the effect of cholesterol depleting agents.
These data suggest that TJ modulation can be achieved by changing
the lipid composition of the cellular membranes or TJ-associated lipid
rafts of barrier forming cells (Fig. 1).
4. Modulators acting directly on TJ components
Better understanding the molecular mechanisms that regulate the
paracellular pathway led to the discovery of novel TJ modulators that
directly and speciﬁcally interact with the extracellular loops of TJ
proteins and the TJ-associated membrane microdomains [43,83–85].
These peptides, enzymes or lipids can be potentially used as new
excipients to safely and reversibly open TJs for delivery of hydrophilic
compounds and biopharmaceuticals (Table 1).
4.1. Occludin
Occludin is the ﬁrst TJ protein, where modulation of TJ perme-
ability by a peptide interacting with its extracellular loop was
described [86]. The 44 amino acid long OCC2 peptide (Table 2),
binding to the second extracellular domain of occludin induced a
reversible increase in paracellular permeability by an increased
turnover of cellular occludin in kidney epithelial cells [86]. The effect
was speciﬁc, because ZO-1, ZO-2, cingulin, and E-cadherin levels
and distribution were unaltered by OCC2 treatment. The sameism Modulator substance Reference
analogue Synthetic peptide [86]
analogue 9–10 amino acid peptides [87]
analogue 14 amino acid lipopeptide OP90–103 [88,89]
used occluding ΔFSH-fused occludin peptide [90]
analogues 4–25 contiguous amino acid peptides [91]
of ﬁrst EC loop Der P1 cysteine proteinase [92]
pression Antisense oligonucleotide [93]
pression siRNA [94]
ptor C-terminal region of CPE [95]
pression siRNA [94]
analogues 4–25 contiguous amino acid peptides [91]
of claudin-23 8–20 contiguous amino acid peptides [96]
analogues 4–25 contiguous amino acid peptides [91]
pression siRNA [94]
ain analogue HAV 6-mer peptide [97]
ain analogue ADT 6-mer peptide [97]
ctivation Vibrio cholerae Zot (45 kDa) [98–100]
ctivation ΔG (Zot active fragment; 12 kDa) [101]
ctivation Zonulin [102]
ctivation AT-1002 [103]
ssociation PGPC and glycero-3-phosphocholines [85]
analogues PN peptides [104,105]
grading enzymes Heparinases, chondroitinases [106]
r; FSH, follicle stimulating hormone; GAG, glycosaminoglycan; JAM, junctional adhesion
osphocholine; PKC, protein kinase C; siRNA, small interfering ribonucleic acid; TJ, tight
Table 2
Amino acid sequence of selected peptide tight junction modulators
Peptide TJ modulator Amino acid sequence Reference
Occludin
Occludin 44-mer peptide 184 GVNPQAQMSSGYYYSPLLAMCSQAYGSTYLNQYIYHYCTVDPQE [86]
Occludin 22-mer peptide 209 NH2-GSQIYTICSQFYTPGGTGLYVD-COOH [82,90]
Lipopeptide OP90–103 H2N-CHR-CONH-DRGYGTSLLGGSVG [88,89]
Occludin 10-mer peptide 100 SNYYGSGLSY [87]
Occludin 9-mer peptide 100 SNYYGSGLS [87]
7-mer peptide FDFWITP [107]
Occludin 6-mer peptide B (cyclic) H-CLYHYC-OH [108]
Claudin-4
C-CPE 1 DIEKEILDLA AATERLNLTD ALNSNPAGNL YDWRSSNSYP WTQKLNLHLT [95]
51 ITATGQKYRI LASKIVDFNI YSNNFNNLVK LEQSLGDGVK DHYVDISLDA
101 GQYVLVMKAN SSYSGNYPYS ILFQKF
C-CPE C-terminal 30-mer NH2-SLDAGQYVLV MKANSSYSGN YPYSILFQKF-OH [109]
C-CPE C-terminal 16-mer NH2-SSYSGNYPYS ILFQKF-OH [110]
E-cadherin
E-cadherin 6-mer HAV-6 Ac-SHAVSS-NH2 [111]
E-cadherin 6-mer ADT-6 Ac-ADTPPV-NH2 [111]
Zonula occludens toxin
Vibrio cholerae Zot; 45 kDa (zonula occludens toxin) 1 MSIFIHHGAP GSYKTSGALW LRLLPAIKSG RHIITNVRGI NLERMAKYLK [112]
51 MDVSDISIEF IDTDHPDGRI TMARFWHWAR KDAFLFIDEC GRIWPPRITA
101 TNLKALDTPP DLVAEDRPES FEVAFDMHRH HGWDICLTTP NIAKVHNMIR
151 EAAEIGYRHF NRATVGLGAK FTITTHDAAN SGQMDSHALT RQVKKIPSPI
201 FKMYASTTTG KARDTMAGTA LWKDRKILFL FGMVFLMFSY SFYGLHDNPI
251 FTGGNDATIE SEQSEPQSKA TAGNAVGSKA VAPASFGFCI GRLCVQDGFV
301 TVGDERYRLV DNLDLPYRGL WATGHHLYKD KLTVFFETES GSVPTELFAS
351 SYRYKVLPLP DFNHFVVFDT FAAQALWVEV KRGLPLKTEN DKKGINSIF
ΔG; 12 kDa (Zot active fragment) 265 EPQSKA TAGNAVGSKA VAPASFGFCI GRLCVQDGFV [112]
301 TVGDERYRLV DNLDLPYRGL WATGHHLYKD KLTVFFETES GSVPTELFAS
351 SYRYKVLPLP DFNHFVVFDT FAAQALWVEV KRGLPLKTEN DKKGINSIF
AT-1001 (FZI/0 synthetic inhibitor) GGVLVQPG [103,113]
AT-1002 (Zot active domain) FCIGRL [112]
Not disclosed target
PN 159 NH2-KLALKLALKALKAALKLA-amide [104,105]
PN 393 (all D-substituted) NH2-klalklalkalkaalkla-amide [104]
PN 407 NH2-LKlLKkLlkKLLkLL-amide [104]
PN 425 NH2-KLAWKLALKALKAALKLA-amide [104]
PN 427 NH2-KLAWKLALKALKAAWKLA-amide [104]
PN 679 CNGRCGGKKKLKLLLKLL [105]
PN 745 LRKLRKRLLRLRKLRKRLLR-amide [105]
Abbreviations: ADT-6, ADT 6-mer peptide corresponding to the bulge in E-cadherin EC-1 domain; C-CPE, C-terminal peptide of Clostridium perfringens enterotoxin; HAV-6, HAV 6-mer
peptide corresponding to the groove in E-cadherin EC-1 domain; OP90–103, occludin peptide 90–103; TJ, tight junction; Zot, zonula occludens toxin.
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mouse mammary epithelial cell line, but induced the formation of
unpolarized multi-layered cell clusters [114]. Parallelly, upregulation
and translocation of AJ protein β-catenin was induced, and through
β-catenin/TCF/LEF activation led to the upregulation of the
protooncogene c-myc [114].
Oligopeptides (9-mer and 10-mer) homologous to segments of the
ﬁrst external loop of occludin impaired junctional resealing on
cultured epithelial cells in a reversible manner without altering ZO-1
localization [87].
A 14 amino acid long peptide, OP90–103, corresponding to the N
terminus of the ﬁrst extracellular loop of occludin and containing a
lipoamino acid to protect it from degradation and aggregation
increased TJ permeability in Caco-2 cells treated apically [88]. The
effect of OP90–103was rapid, transient, and caused noshort-term toxicity.
The peptide reduced TEER and increased 70 kDa dextran transport in a
concentration-dependent manner in human primary airway epithelial
cells [89] (Table 3). Treatment with OP90–103 peptide resulted in
enhanced gene transfer efﬁciency of epithelial cells with adenovirus
vectors due to TJ opening, increased penetration to the basolateral
membrane, and greater viral binding and internalization [89].
Organ-speciﬁc targeting of a 22 amino acid long peptide interact-
ingwith the second extracellular loop of occludin [86] (Tables 1 and 2)has been demonstrated in the blood–testis barrier in rats [90] (Tables
1–3). A genetically engineered follicle-stimulating hormone (FSH)
mutant protein which binds to Sertoli cells was used as a testis-
speciﬁc carrier in the study. The occludin peptide linked to the mutant
FSH induced transient and reversible disruption of the blood–testis
barrier without compromising the TJ-barrier integrity in epithelia of
kidney, liver, and small intestine [90]. This study indicates that
targeting of peptides interacting with TJ proteins by receptor ligands
may confer organ selectivity to barrier opening.
Disturbance of TJ function by directly targeting TJ proteins cannot
only inﬂuence the ﬂux of solutes, but also cellular transmigration. A
cyclic occludin peptide antagonist, peptide B, containing a conserved
occludin cell adhesion recognition sequence consistently and sig-
niﬁcantly increased neutrophil leukocyte migration across human
umbilical vein endothelial cell layers in a time- and dose-dependent
manner [108]. The increased chemotaxis correlated with disorganiza-
tion of occludin, but not VE-cadherin in endothelial cells [108].
Another approach to modify permeability is the enzymatic
cleavage of TJ proteins. Der p1, a major allergen from the house dust
miteDermatophagoides pteronyssinus and a cysteine proteinase, causes
cell detachment in cultured kidney and tracheal epithelial cell layers
and increases the permeability of isolated sheets of bronchial mucosa
[92,150]. The time-dependent reversible disruption of TJ morphology
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associated with cleavage of occludin [92]. The substrate of Der p1 is
the ﬁrst extracellular loop of human occludin, and potential cleavage
sites exist in both extracellular loops of claudin-1 [92].
4.2. Claudins
Sequence similarities between claudin-1 and -2 and the cloned
receptor for Clostridium perfringens enterotoxin (CPE) causing food
poisoning led to the identiﬁcation of the receptor for CPE as claudin-4
[153]. CPE can also bind to claudin-3, -6, -7, -8, and -14 [154], the
majority of claudins found in the GI tract. The C-terminal fragment of
CPE (C-CPE), the binding domain of the toxin, selectively removed
claudin-4 from TJs and disintegrated TJ strands in MDCK epithelial
cells [95]. Parallelly with themorphological changes the TJ barrier was
downregulated in a time- and dose-dependentmanner [95]. A peptide
sequence containing the C-terminal 16 amino acids of C-CPE (Table 2)
was found to be responsible for the interaction with the second
extracellular domain of claudin-4 and the disruption of TJs [109,110].
Treatment of Caco-2 cells with C-CPE resulted in a decrease in TEER
[110]. C-CPE enhanced the absorption of 4 kDa and 10 kDa dextran
(but not that of 20 and 40 kDa) in rat jejunum [42,109,117]. C-CPE at
0.1 mg/ml concentration was as effective absorption enhancer as
sodium caprate used in 40 mg/ml concentration, while no mucosal
toxicity was observed [43,84,117]. The absorption enhancing effect of
C-CPEwas observed in the jejunum, but not in colon of rats, in contrast
to sodium caprate, which was effective in both regions [117].
These ﬁndings indicate that claudin-4 can be a target of TJ
modulators, like C-CPE. Other antagonists of claudin-4, including
antibodies, antibody fragments, and small interfering nucleic acids
may also have the potential to open epithelial TJs and to enhance
paracellular transport (Table 1) [94].
4.3. Zonulin
Zonula occludens toxin (Zot) of V. cholerae (Table 2) reversibly
increases intestinal permeability by interacting with a surface
receptor, activating PKC-α leading to disassembly of TJs [99]. Human
zonulinwas identiﬁed as the endogenousmammalian analogue of Zot,
sharing a conserved N-terminal sequence corresponding to the
putative receptor binding site [113]. A 45 kDa glycoprotein binding
Zot and zonulin was demonstrated in brain [155], in the epithelium of
the nasal region and the small intestine [101]. This correlateswell with
the in vivo tissue speciﬁcity of Zot, which is active only on the mucosal
side of endothelial cells and epithelial cells in the nasal region, the
jejunum and ileum, but not in the colon or kidney (Table 3) [156]. Zot
and zonulin also bind β-tubulin, and this interaction can contribute to
their TJ regulating action [157].
The TJ modulator and AE effects of Zot and active fragments
derived from it, ΔG and AT1002 peptides, were demonstrated on
several models (Table 3), including nasal and intestinal epithelium
and cultured brain endothelial cells. Zot reversibly enhanced the
intestinal permeability to insulin and immunoglobulins in rabbits
[100]. Zot also induced a rapid and reversible decrease in TEER of
brain endothelial monolayers and an increase in paracellular
permeability for markers sucrose and inulin, and P-glycoprotein
(Pgp) efﬂux pump ligand drugs doxorubicin and paclitaxel [158]. Zot
also acts as an adjuvant for mucosal antigen delivery and induced
protective immune responses to ovalbumin and tetanus toxoid
through the intranasal and rectal routes [139]. The Zot fragment ΔG
enhanced the oral bioavailability of hydrophobic drugs interacting
with Pgp, such as cyclosporin A, ritonavir, saquinavir and acyclovir
[115]. AT1002, a 6-mer synthetic peptide fragment of Zot, enhances
the in vivo intestinal absorption of cyclosporin A in rats [116], and the
nasal absorption of large hydrophilic markers 4 kDa polyethylene
glycol (PEG) and inulin [144]. Beside the intestinal and nasal routes,AT1002 can potentially facilitate the pulmonary delivery of thera-
peutic agents (Table 3) [103].
Although the Zot and zonulin receptor and its signalling cascade
leading to TJ opening have not been characterized fully yet, active
peptide fragments of Zot seem to be promising agents to safely and
effectively improve drug and vaccine delivery across mucosal barriers
and the BBB.
4.4. E-cadherin
Peptides, derived from the E-cadherin EC-1 domain containing
HAV amino acid sequence can inhibit E-cadherin mediated cell–cell
adhesion and modulate the intercellular junctions of cell monolayers
[45,97]. The calcium-mediated cell adhesion of cultured brain
endothelial cells was prevented by HAV peptide [45]. Beside HAV
peptides, corresponding to the groove region of EC-1 domain, ADT
sequences containing peptides of the bulge region of E-cadherin were
identiﬁed, and they were also able to increase paracellular perme-
ability in MDCK cells [97]. HAV and ADT hexapeptides (Table 2),
interfering with the homophilic binding of E-cadherin, could time and
dose-dependently reduce TEER and increase the paracellular trans-
port of mannitol across the epithelial cell layers [97].
4.5. Other targets
In a recent paper four groups of lipids, sphingosines, alkylgluco-
sides, oxidized lipids and ether lipids, have been identiﬁed as non-
toxic and reversible TJ modulators [85]. Treatment of brochial/
tracheal epithelial tissues with individual lipids, among them 1-1-
palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) resulted
in a rapid reduction of TEER, up to 95%, which was restored within 1 h.
Lipid treatment could also increase the permeability of the barrier
tissue for ﬂuorescein isothiocyanate (FITC)-labelled 3 kDa dextran and
for the 4 kDa human peptide YY3–36 [85]. No changes in TJ structural
morphology were found by immunoﬂuorescence microscopy.
Although the exact mode of action of these lipid TJ modulators are
not disclosed, cell membrane lipid composition and/or lipid rafts
cannot be excluded as their targets.
A novel tight junction modulator peptide, PN159 (Table 2), has
been described and tested by the same group [83,85,145]. PN159
shows a dose-dependent reduction of TEER with a rapid onset, quick
recovery of the barrier functions on removal and good cell viability
and low cytotoxicity. Parallelly with the changes in TEER, PN159
enhanced the permeability for galantamine, calcitonin, human
parathyroid hormone 1–34 and peptide YY3–36 on an in vitro tissue
model (Table 3) [85,145]. In a rabbit model PN159 enhanced the
systemic bioavailability of human peptide YY3–36 via intranasal
administration [145]. The speciﬁc molecular target of PN159 has not
been published, but the extracellular domain of an integral membrane
TJ protein cannot be excluded, since the peptide was identiﬁed by
phage display on EGTA-treated human brochial epithelial cells [83].
PN159 can be a safe and potent TJ modulator to enhance drug delivery
by nasal and gastrointestinal routes of administration [85]. Several
peptides from the PN series (Table 2) may have a TJ modulator effect
similar to PN159 (Table 3).
On the analogy of claudin-4 modulators, antagonists of JAMs,
peptides, antibodies, and small interfering nucleic acids, may also
regulate paracellular permeability of TJs [94].
5. TJ modulating effects of absorption enhancers/paracellular
permeability enhancers
The controlled and reversible opening of tight junctions in the
biological barriers to enhance drug delivery by safe and effective AEs
or paracellular permeability enhancers (PPEs) is a long time goal in
pharmaceutical and biomedical research (Table 4). However, the
Table 3
Tight junction modulators used in epithelial barriers of peripheral organs
Modulator substance Organ/tissue/cell culture Drug/tracer Reference
Gastrointestinal tract epithelium
Duodenal
ΔG (Zot fragment; 12 kDa) In vivo, rat intraduodenal cannula Cyclosporin A, saquinavir; ritonavir, acyclovir [115]
AT-1002 In vivo, rat intraduodenal cannula Cyclosporin A, protease inhibitors [116]
Jejunal
Zot (45 kDa) Ex vivo, rabbit, Ussing Insulin, immunoglobulins, PEG 4000 [100]
Zonulin (47 kDa) Ex vivo, Rhesus monkey, Ussing [Decreased tissue resistance] [113]
C-CPE In situ, rat, loop assay FITC-dextran 4 kDa, 10 kDa [109,117]
Sodium caprate In situ, rat, loop assay FITC-dextran 4 kDa [117]
Dimethyl-β-cyclodextrin In situ, rat, loop assay Insulin [118]
NO donors (NOC5, NOC12) Ex vivo, rat, Ussing chamber 5(6)-carboxyﬂuorescein [119]
NO donors (SNAP, NOC5 and 12) Ex vivo, rat, Ussing chamber Insulin, eel calcitonin [120]
NO donors (SNAP, NOC5 and 12) In situ, rat, loop assay 5(6)-carboxyﬂuorescein [121]
Ileal
Zot (45 kDa) Ex vivo, rabbit, Ussing [Decreased tissue resistance] [99]
Zot (45 kDa) Ex vivo, rabbit, Ussing Insulin, immunoglobulins, PEG 4000 [100]
Zonulin (47 kDa) Ex vivo, Rhesus monkey, Ussing [Decreased tissue resistance] [113]
Sodium caprate In vivo, rat Polysucrose [122]
NO donors (SNAP, NOC5 and 12) Ex vivo, rat, Ussing chamber Insulin, eel calcitonin [120]
Colonic
Zonulin (47 kDa) Ex vivo, Rhesus monkey, Ussing [Decreased tissue resistance] [113]
Zot (45 kDa) In vitro, Caco-2 monolayers Mannitol, sucrose, inulin, PEG 4000 [123,124]
Zot (45 kDa) In vitro, Caco-2 monolayers Paclitaxel, doxorubicin, cyclosporin A, acyclovir, enaminones [123,124]
Lipopeptide OP90–103 In vitro, Caco-2 monolayers TEER↓, mannitol [88]
C-CPE In vitro, Caco-2 monolayers TEER↓, FITC-dextran 4 kDa [109]
EDTA In vitro, Caco-2 monolayers carboxyﬂuorescein, PEG 4000, furosemid, FITC-dextran [125,126]
Oleic acid In vitro, Caco-2 monolayers TEER↓ mannitol [127,128]
Sodium caprate In situ, rat, loop assay FITC-dextran 4 kDa [117]
Sodium caprate In situ, rat, loop assay 5(6)-carboxyﬂuorescein [121]
Sodium caprate In vitro, Caco-2 monolayers Mannitol [129,130]
Long-chain acylkarnitine Ex vivo, rat TEER↓ [131]
Long-chain acylkarnitine In vitro, Caco-2 monolayers TEER↓ [132]
Sodium dodecyl sulfate In vitro, Caco-2 monolayers TEER↓ mannitol [133,134]
Polysorbate 20, Solulans In vitro, Caco-2 monolayers TEER↓ metformin [135]
Nonylphenol ethoxylates In vitro, Caco-2 monolayers Mannitol, daunomycin [136]
Bile salts In vitro, Caco-2 monolayers TEER↓ mannitol, PEG [133]
Chitosans In vitro, Caco-2 monolayers TEER↓ inulin [137,138]
NO donors (NOC5, NOC12) Ex vivo, rat, Ussing chamber 5(6)-carboxyﬂuorescein [119]
NO donors (SNAP, NOC5 and 12) Ex vivo, rat, Ussing chamber Insulin, eel calcitonin [120]
NO donors (SNAP, NOC5 and 12) In situ, rat, loop assay 5(6)-carboxyﬂuorescein [121]
Rectal
His-Zot In vivo, mouse Tetanus toxoid [139]
E. coli heat labile enterotoxin In vivo, mouse Tetanus toxoid [139]
Sodium caprate In vivo, human Ampicillin [140]
Cyclodextrins In vivo, rabbit Insulin [141]
NO donors (SNAP, NOR1 and 4) In vivo, rabbit Insulin [142]
Airway epithelium
Nasal
His-Zot In vivo, mouse Ovalbumin, tetanus toxoid [139]
MBP-Zot In vivo, mouse Ovalbumin, tetanus toxoid [139]
Zot In vivo, mouse Gliadin [143]
AT-1002 In vivo, rat PEG 4000, inulin [144]
E. coli heat labile enterotoxin In vivo, mouse Ovalbumin, tetanus toxoid [139]
PN 159 In vivo, rabbit Peptide YY3–36 [104,105,145]
PN 27, 58, 73, 202, 183, 228, 556 In vivo, rabbit Peptide YY3–36 [105]
EGTA In vivo, human TEER↓ [146]
Bile salts In vitro, human NEC fexofenadine [147]
Cyclodextrins In vivo, rabbit Insulin [148]
Dimethyl-β-cyclodextrin In vivo, rat TEER↓ mannitol, enoxaparin [149]
NO donor SNAP In vivo, rabbit rh Granulocyte colony-stimulating factor [148]
Pulmonary
PN 159 In vitro, human REC Calcitonin, parathormone, galantamine, MC-4RA [104,105]
PN 159, PN393, PN407, In vitro, human REC FITC-dextran (3 kDa), TEER↓ [104]
PN679, PN745, PN434, PN408 In vitro, human REC FITC-dextran (3 kDa) [105]
AT-1002 In vitro, human REC FITC-dextran (4 kDa), TEER↓ [103]
AT-1002 In vivo, rat (instillation to lung) Calcitonin [103]
FDFWITP 7-mer peptide In vitro, human BEC TEER↓ [107]
Lipopeptide OP90–103 In vitro, human REC TEER↓, FITC-dextran (70 kDa), adenovirus vector [89]
Der p1 cysteine proteinase In vitro, canine TEC Albumin [92,150]
PGPC In vitro, human REC TEER↓ FITC-dextran (3 kDa), peptide YY3–36 [85]
EDTA/EGTA/BAPTA In vitro, human REC TEER↓ gene transfer [146]
EGTA In vivo, rabbit trachea TEER↓ [146]
EGTA In vitro, human REC TEER↓ mannitol, dextran, adenoviral transfer [151]
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Modulator substance Organ/tissue/cell culture Drug/tracer Reference
^
Airway epithelium
Pulmonary
Oleic acid In vitro, human REC mannitol [152]
Sodium caprate In vitro, human REC TEER↓ mannitol, dextran, adenoviral transfer [151]
Blood–testis barrier
ΔFSH-fused occludin peptide In vivo, rat FITC-inulin [90]
Abbreviations: BAPTA, 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid; BEC, bronchial epithelial cells; C-CPE, C-terminal fragment of Clostridium perfringens enterotoxin;
EDTA; ethylenediamine-N,N,N′,N′-tetraacetic acid; EGTA, ethylene glycol-bis(beta-aminoethyl ether)-N,N,N′,N′-tetraacetic acid; FITC, ﬂuorescein isothiocyanate; FSH, follicle
stimulating hormone; His-Zot, zonula occludens toxin tagged at the N-terminus with a hexahistidine tail; MBP-Zot, zonula occludens toxin fused with the maltose-binding protein;
MC-4RA, melanocortin-4 receptor agonist; NEC, nasal epithelial cells; NOC5, [3-(2-hydroxy-1-(methylethyl)-2-nitrosohydrazino)-1-propanamine]; NO, nitric oxide; NOC12,
[N-ethyl-2-(1-ethyl-hydroxy-2-nitrosohydrazino)-ethanamine]; NOR1, (+/−)-(E)-4-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexenamide; NOR4, (+/−)-N-[(E)-4-
Ethyl-2-[(Z)-hydroxyimino]-5-nitro-3-hexene-1-yl]-3-pyridine carboxamide; PEG 4000, polyethylene glycol 4 kDa; REC, respiratory epithelial cells; rh, recombinant human; SNAP,
S-nitroso-N-acetyl-DL-penicillamine; TEC, tracheal epithelial cells; TEER↓, decrease in transepithelial electrical resistance; Zot, zonula occludens toxin (45 kDa).
Table 3 (continued)
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was scarce in the past. The ﬁrst integral membrane protein of the TJ
complex, occludin was discovered in 1993 [25] and in the last
15 years a great progress has been achieved with the discovery of
new TJ, AJ and adaptor proteins and protein families, signalling
molecules and pathways [3]. Because of this fact AEs and PPEs
developed before the discovery of the molecular composition and
function of TJs have a rather unspeciﬁc mode of action (Table 4).
Most importantly, the difference between the effective and toxic
doses of these AEs is small [7]. Despite these drawbacks some of the
AEs, e.g. sodium caprate (C10), are effective and clinically used in
oral formulations.
Some of the AEs enhancing transdermal drug delivery, like
surfactants and fatty acids, are able to increase buccal permeability.
However, the mode of action of AEs is dissimilar in the skin and buccal
mucosa due to the different morphological and molecular structure of
the two barriers [177]. Therefore, AEs might be effective in one barrier,Table 4
Absorption enhancers, miscellaneous tight junction modulators and non-speciﬁc targets
Modulator substance Possible target/m
Chelators
EGTA, EDTA, BAPTA Ca↓, PKC, AJ and
Fatty acids, modiﬁed fatty acids, phosphate esters, phospholipids
Oleic acid Lipid rafts, PKC,
Sodium caprate PLC, PI3, redistri
Palmitoyl carnitine PKC, gap junctio
Lysophosphatidic acid PKC, MAPK, gap
Surfactants
Sodium dodecyl sulfate Actin reorganiza
Bile salts: sodium cholate, dehydrocholate, taurocholate Ca↑, F-actin reor
Cationic polymers, polycations
Protamine Negative surface
Poly-L-Lys, poly-L-Arg PKC, phospholip
Chitosan PKC-α, redistribu
Cyclodextrins
Dimethyl-β-CD Cholesterol depl
Nitric oxide donors, bradykinin
Cereport, DEA-NONOate, PAPA-NONOate Ca↑, cyclic GMP↑
Hyperosmotic solutions
Mannitol Src kinase, β-cat
High frequency focused ultrasound
MRI-guided high frequency focused ultrasound/Optison Vasoconstriction
Abbreviations: AJ, adherens junction; AP-1, activator protein 1 transcription factor; BAPTA, 1,
calcium ions; Ca↑, increase in intracellular calcium ion concentration; CD, cyclodextrin; cyclic
diethylamino)diazen-1-ium 1,2-diolate; EDTA; ethylenediamine-N,N,N′,N′-tetraacetic acid
calcium-activated potassium channel; MAPK, mitogen activated protein kinase; MRI, magneti
1-[N-(2-aminopropyl)-N-(2-ammonio propyl)amino]diazen-1-ium 1,2-diolate; PI3, phosph
junction; ZO-1, zonula occludens protein 1.but not in the other, and although they are able to act on several
barriers, their local action can be different.
5.1. Chelators
Calcium chelators, like ethylenediamine-N,N,N′,N′-tetraacetic acid
(EDTA), ethylene glycol-bis(beta-aminoethyl ether)-N,N,N′,N′-tetra-
acetic acid (EGTA), and 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-
tetraacetic acid (BAPTA) increase paracellular permeability through
disruption of AJs and TJs via activation of PKC [159]. EDTA enhances the
permeability of Caco-2 monolayers for polyethylene glycol 4000 [125],
furosemide, carboxyﬂuorescein [126], and FITC-dextran without
serious cytotoxicity [178]. EDTA, EGTA and BAPTA in a hypotonic buffer
caused a rapid, reversible drop in TEER and facilitated gene transfer
with retrovirus or adenovirus from the apical side on cultured human
differentiated airway epithelial cells by opening the intercellular TJs
[146]. Chelators applied to rabbit tracheal epithelia or human nasalechanism Reference
TJ disassembly [159]
gap junction [160,161]
bution of TJ proteins [129,130]
n [162]
junction, redistribution of TJ proteins [163,164]
tion, Ca↑, AP-1 and NF-Κb [134,165]
ganization [147,166]
charge↓, actin reorganization; occludin, claudin-1↓ [167,168]
ase D [169]
tion of actin, occludin, ZO-1 [137,138,170,171]
etion, lipid rafts, TJ disruption [172,173]
, KCa channel activation, TJ opening [174]
enin phosphorylation, redistribution of TJ proteins [175]
, transcytosis, TJ disruption [176]
2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid; Ca↓, removal of extracellular
GMP, cyclic guanosine monophosphate; DEA-NONOate, diethylammonium (Z)-1-(N,N-
; EGTA, ethylene glycol-bis(beta-aminoethyl ether)-N,N,N′,N′-tetraacetic acid; KCa,
c resonance imaging; NF-κB, nuclear factor-κB transcription factor; PAPA-NONOate, (Z)-
atidylinositol 3,4,5-triphosphate; PKC, protein kinase C; PLC, phospholipase C; TJ, tight
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sensitivity, suggesting that epithelial junctions opened. Importantly,
this novel formulation enhanced both retroviral- and adenoviral-
mediated gene transfer to rabbit tracheal epithelia in vivo [146].
Chelation of calcium to open epithelial apical junctions could allow the
targetingof airwaycellswithprogenitor capacity that are located below
the surface layer to attain persistent gene transfer [146]. This study
indicates the potential clinical usefulness of chelators as TJ modulators.
5.2. Fatty acids, modiﬁed fatty acids and phosphate esters
Oleic acid is one of the most popular AEs, used in transdermal drug
delivery vehicles, patches, and microemulsions [179,180]. It is known
to modulate the structure of membranes. Recent data indicate, that it
does not perturb signiﬁcantly the structure of lipid bilayers, and its
effects can be restricted to more condensed membrane structures,
such as the gel phase, more characteristic to cholesterol-containing
ordered domains, like lipid rafts [160]. Oleic acid decreased TEER
[127,128] and increased mannitol ﬂux in Caco-2 cells, parallelly with
disintegration of cell–cell contacts [128] (Tables 3, 4). Oleic acid also
enhanced the permeability of mannitol across cultured alveolar
epithelial cells in a calcium-dependent way [152]. Beside its effect on
epithelial barrier, reversible opening of the BBB was induced by oleic
acid or oleic acid emulsion injected to the carotid artery in animal
studies [181,182]. The data listed above suggest that beside its effect on
membrane ﬂuidity, oleic acid can increase paracellular permeability of
dermal, gastrointestinal, alveolar and blood–brain barriers
[127,128,152,179–182]. The exact target of oleic acid is not known,
butmembranemicrodomains or lipid rafts could be among them [160].
Sodium caprate, amedium chain fatty acid (C10), and a constituent
of milk fat, is an absorption enhancer used in clinical therapy. It
enhanced the permeability of mannitol in Caco-2 monolayers by
redistribution of the cytoskeleton, TJ proteins ZO-1 and occludin, and
opening of TJs through phospholipase C-dependent inositol tripho-
sphate/diacylglycerol pathways [129,130,183] (Table 4). Sodium
caprate also increased TJ permeability and the transport of poly-
sucrose in rat ileum [122], and ampicillin bioavailability after rectal
administration in humans [140]. It should be noted, that reversible
mucosal damage could be observed after sodium caprate exposure
[140]. On another type of barrier, sodium caprate-induced TEER drop,
increased mannitol and dextran permeability, adenoviral lacZ gene
transfer was more effective in airway epithelial cells than the EGTA-
induced changes [151]. A redistribution of claudin-1, found following
C10 but not EGTA treatment, is hypothesized as a possible mechanism
of gene-transfer enhancement by C10 [151].
Palmitoyl carnitine, a long-chain (C16) fatty acid ester, greatly
enhances the absorption of hydrophilic drugs across intestinal mucosa
[131], and across Caco-2 epithelial cells accompanied by a rapid and
reversible drop in TEER and opening of TJs [132] (Table 3). However,
transport enhancement was accompanied by an increase in apical
membrane permeability and a reduction in cell viability [184]
indicating insufﬁcient separation between efﬁcacy and toxicity.
5.3. Surfactants
Surfactants are solubilizing excipients widely used in oral, injectable
and nasal formulations [185,186]. Anionic, non-ionic synthetic surfactants
and bile salts have been extensively studied to enhance transepithelial
permeability for differentmarkermolecules, peptides anddrugs (Table 3),
but their effect on TJs is less well characterized (Table 4).
Sodium dodecyl sulfate (SDS), an anionic surfactant had an
immediate effect on paracellular permeability of Caco-2 cells, the
TEER dropped, intracellular calcium levels increased, and TJs sepa-
rated [133,134]. While short-term incubation of cells with SDS caused
reversible enhancement of mannitol permeability, longer exposure
resulted in irreversible changes and apical membrane injury andcellular toxicity [133,134]. The toxicity of surfactants polyoxyethylene
9 lauryl ether and sodium glycocholate given at high concentration
(1%) was demonstrated after administration to rat lungs, where they
induced acute inﬂammation [187].
Non-ionic surfactants polysorbate 20, oxyethylene ether Solulan
C24 and C16 showed a concentration dependent paracellular increase
in metformin transport, parallelly with TEER decrease, however,
increased permeability correlated with decreased cell viability of
Caco-2 cells [135]. Nonylphenol ethoxylates can also rapidly and
reversibly open paracellular TJs and enhance the transport of mannitol
and daunomycin, but these non-ionic surfactants also cause irrever-
sible changes in long-term treatments [136].
Bile salts, sodium cholate, sodium taurocholate and sodium
taurodeoxycholate, which are ionic surfactants, show also a concentra-
tion-dependent effect on epithelial permeability and morphology in
Caco-2 cells and human nasal epithelial cells, respectively [133,147]. A
dose dependent reduction of cell viability was also observed at higher
than critical micelle concentration, but bile salts exerted less toxicity,
than non-ionic surfactants Tween 80 and Poloxamer F68 [147].
5.4. Cationic polymers
Cationic polymers, like poly-L-lysines, polyethyleneimine and
chitosan, are able to induce reversible opening of TJs in epithelial
cell models [137,188,189]. Chitosan and its derivatives are non-toxic
biocompatible polymeric AEs obtained from chitin. Because of their
mucoadhesive as well as AE properties these cationic polysaccharides
have been extensively studied as excipients for drug delivery across
dermal, gastrointestinal, nasal, and pulmonary epithelial barriers
(Table 3) [186,190–192]. The chitosan-induced reversible increase in
TJ permeability involves the redistribution of occludin, ZO-1 and the
actin-cytoskeleton [137,170,171]. The process is mediated by activation
of PKC-α in Caco-2 cells [138,193]. Because of their low toxicity, good
water solubility, mucoadhesive properties in addition to their TJ
modulator effect, chitosan derivatives are promising candidates to
enhance drug delivery in clinical setting.
5.5. Cyclodextrins
Cyclodextrins (CDs) are natural cyclic oligosaccharides derived
from starch and used as excipients in marketed pharmaceutical
products [194]. CDs in pharmaceutical products are mainly used as
complexing agents. The potential of CDs to be used as penetration
enhancers for drugs has been investigated on several models
[118,141,148,149,170,194,195] (Table 3). Dimethyl-β-CD is a potent
enhancer of nasal and intestinal absorption of heparins and insulin in
vivo and in vitro [118,141,148,149,170,195]. The dimethyl-β-CD-
induced increase in the permeability for mannitol and enoxaparin
was accompanied by reduction of TEER and changes in ZO-1
distribution in epithelial cells, indicating opening of TJs [149].
Dimethyl-β-CD was found to be more effective to enhance bioavail-
ability and absorption of heparin and insulin than all other CDs tested,
hydroxypropyl-β-CD, α-, β-γ-CD [141,148,149,195]. This effect seems
to correlate with the cholesterol depleting efﬁcacy of CDs
[172,173,196] (Table 4). Beside other well characterized effects of
CDs on drug complexation and unstirred water layer [194], cholesterol
depletion from epithelial cell membrane, especially from lipid rafts,
and subsequent loss of TJ integrity, displacement of TJ proteins can
explain the AE effect of dimethyl-β-CD [81,82]. However, the
cholesterol depleting effect of CDs also correlate with their cytotoxi-
city on epithelial and BBB in vitro models [172,196,197].
5.6. Nitric oxide donors
NO is a regulator of epithelial TJs, and excessive levels of NO
generated by activated inducible NO synthase result in epithelial
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expression and dislocation of TJ proteins occludin, ZO-1, -2 and -3
are accompanied by enhanced transport of FITC-dextran across the
ileal mucosal membrane were observed [199].
NO donor molecules, S-nitroso-N-acetyl-DL-penicillamine (SNAP),
(2-hydroxy-1-methylethyl-2-nitrosohydrazino)-N-methyl-1-propa-
namine (NOC7), (2-hydroxy-1-(1-methylethyl)-2-nitrosohydrazino)-
1-propanamine (NOC5), and N-ethyl-2-(1-ethyl-2-hydroxy-2-nitro-
sohydrazino)-ethanamine (NOC12) have been tested as potential AEs
in epithelial barriers of the gastrointestinal tract and in the nasal
mucosa [119–121,142,200–202] (Table 3). SNAP enhanced the intest-
inal absorption of insulin, and calcitonin in rabbits and rats, and the
nasal absorption of human granulocyte colony-stimulating factor in
rabbits [120,142,201]. When compared with other AEs, like sodium
glycocholate and sodium caprate, SNAP was the most effective AE in
the small intestine showing excellent effectiveness at low concentra-Table 5
Modulators used for the opening of the tight junctions at the blood–brain barrier
Modulator substance Organ/tissue/cell culture
Modulators acting on tight junctions
Zonula occludens toxin (45 kDa) In vitro, bovine BMVEC
Zonula occludens toxin (45 kDa) In vitro, bovine BMVEC
ΔG; 12 kDa (Zot active fragment) Intracarotid injection, rat
18β-glycyrrhetinic acid, oleamide In vitro, porcine BMVEC
Cereport (lobradimil) In vitro, human BMVEC
Cereport (lobradimil) Glioma and PD model, rat
Cereport (lobradimil) Glioma model, rat
Cereport (lobradimil) Clinical trials, human
Histamine In vitro, bovine BMVEC
Histamine Glioma model, rat
Absorption enhancers and new therapeutical approaches
Chelators
EGTA In vitro, bovine BMVEC
BAPTA In vitro, porcine BMVEC
Fatty acids, modiﬁed fatty acids, phospholipids
Oleic acid Intracarotid injection, rat
Linoleic acid and oleic acid emulsion Intracarotid injection, cat
Sodium caprate Intracarotid injection, rat
Lysophosphatidic acid In vitro, porcine BMVEC
Surfactants
Sodium dodecyl sulfate Intracarotid injection, rat
Sodium dehydrocholate Intracarotid injection, rat
Sodium dehydrocholate, TCDC In situ brain perfusion, rat
Sodium dihydroxy-oxo-cholanate Subcutaneous injection, rat [2
Cationic polymers
Protamine In situ brain perfusion, rat
Protamine, poly-L-Lys, poly-L-Arg Intracarotid injection, rat
Chitosan Intravenous injection, mouse
Cyclodextrins
α-CD, β-CD, γ-CD In vitro, bovine BMVEC
Hydroxypropyl-γ-CD, γ-CD In vitro, bovine BMVEC
Rame-β-CD, chrisme-β-CD In vitro, bovine BMVEC
Nitric oxide donors
SNAP In situ brain perfusion, rat
DEA-NONOate, PAPA-NONOate Intracarotid, RG2 tumour, rat
Hyperosmotic solutions
Arabinose In vitro, bovine BMVEC
Arabinose Intracarotid injection, rat
Mannitol In vitro, bovine BMVEC
Mannitol Intraarterial injection, human
Short-chain alkylglycerols
1-O-pentylglycerol Intracarotid injection, rat and
1-O-pentylglycerol Intracarotid, C6 or RG2 tumou
High frequency focused ultrasound
High frequency focused ultrasound Rabbit
High frequency focused ultrasound Mouse
High frequency focused ultrasound Rat
Abbreviations: BAPTA, 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid; BMVEC
diethylammonium (Z)-1-(N,N-diethylamino)diazen-1-ium 1,2-diolate; ΔG, zonula occluden
(beta-aminoethyl ether)-N,N,N′,N′-tetraacetic acid; GABA, γ-aminobutyric acid; γ-AIB, γ-a
PAPA-NONOate, (Z)-1-[N-(2-aminopropyl)-N-(2-ammonio propyl)amino]diazen-1-ium 1,
taurochenodeoxycholate; TEER, transendothelial electric resistance; TJ, tight junction; Zot, ztion [121]. However, the exact mechanism of action is not known, and
the hypothesized effect on TJs was not examined yet.
6. Modulation of TJs at the blood–brain barrier for drug targeting
6.1. Modulators acting on brain endothelial TJs
There are no data yet on the effect of the newly discovered epithelial
TJ modulators on the BBB, except for Zot and its fragments (Table 5).
Integralmembrane TJ proteins occludin, JAMs, claudin-5, AJ proteinsVE-
cadherin and the BBB-speciﬁc cadherin-10 [233], or AHNAK colocalizing
in TJs at the BBB [234], could be all potential targets able to modulate
paracellular permeability in brain endothelial cells. C-CPE is an unlikely
TJ modulator for the CNS, because its target, claudin-4 is absent at the
BBB. On the other hand, lipid modulators, like PGPC may potentially
open the BBB, however, no data exist on their effects on BBB models.Drug/tracer Reference
Sucrose, inulin [158]
Doxorubicin, paclitaxel [158]
Methotrexate, paclitaxel [203]
Mannitol, inulin [204]
Inulin [69]
Loperamide, cyclosporin A [205–207]
Carboplatin, paclitaxel, doxorubicin [207,208]
Carboplatin [209]
Sucrose, inulin, EBA [66]
GABA, EBA [210]
Sucrose [212]
Sucrose [163]
γ-AIB, EBA [181]
Gadolinium [182]
Mannitol [213]
TEER↓ [163]
γ-AIB, EBA [214]
Fluorescein, EBA [215,216]
Mannitol [217] [217]
18] Quinine, morphine, pentobarbital [218]
HRP [167]
Albumin [219]
Nobiletin [220]
Sucrose [172]
Doxorubicin [173]
Doxorubicin [221]
Sucrose [222]
γ-AIB [174]
Sucrose [223]
TJ opening [224]
Sucrose, inulin [225]
Anticancer drugs [226]
mice Fluorescein, albumin [227,228]
r, rat Cisplatin, methotrexate, antibiotics [228]
MRI contrast agents Magnevist, Mion-47 [229]
Antibodies [230,231]
Doxorubicin [232]
, brain microvascular endothelial cell monolayer; CD, cyclodextrin; DEA-NONOate,
s toxin active fragment (12 kDa); EBA, Evans blue albumin; EGTA, ethylene glycol-bis
minoisobutyric acid; HRP, horseradish peroxidase; MRI, magnetic resonance imaging;
2-diolate; PD, Parkinson's disease; SNAP, S-nitroso-N-acetyl-DL-penicillamine; TCDC,
onula occludens toxin.
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coprecipitated with TJ proteins in brain endothelial cells [204]. Blockers
of gap-junctions, 18β-glycyrrhetinic acid and oleamide, impaired the
barrier function of brain endothelial cells, decreased the TEER and
increased the paracellular ﬂux of mannitol and inulin [204]. Interest-
ingly, no change in the expression and localization of occludin, claudin-
5, JAMs or ZO-1 was detected after treatment with gap-junction
inhibitors. These ﬁndings indicate, that gap-junctions can participate
in the barrier function at the BBB and can be targets of TJ modulators.
There are several examples of receptor-mediated activation of
signalling pathways leading to transient opening of TJs at the BBB (for
review see [66]). A Zot-binding glycoprotein was puriﬁed from brain
[155], and Zot is active as a TJ modulator at the brain endothelium. It
induces a reversible, concentration-dependent TEER decrease, and an
increase in the paracellular transport of the permeability markers
sucrose and inulin, indicating TJ opening, without short-term toxicity
in cultured brain endothelial cells [158]. Zot also enhanced the
transport of chemotherapeutic agents doxorubicin and paclitaxel,
ligands of Pgp [158]. The Zot active fragment ΔG, given into the carotid
artery of rats, increased several fold the brain penetration of sucrose,
paclitaxel, and the hydrophilic methotrexate [203] (Table 5).
Vasoactive compounds, such as histamine, bradykinin, or leuko-
trienes are well-known mediators of brain oedema formation and
increase BBB permeability [66,235,236]. Blood vessels in brain tumour
tissue are more sensitive to the permeability enhancing effects of these
mediators, than normal BBB [236]. Structural and functional changes
found in the microvasculature of brain tumours are responsible for loss
of BBB integrity (see for review [237]). Cultured glioblastoma cells and
glioma-derived factors induced downregulation of the expression of
occludin, claudin 1, and claudin 5, and an increase in paracellular
permeability through brain endothelial cell monolayers [238].
Cereport (RMP-7, labradimil), a 9-mer synthetic peptide analogue of
bradykinin increases intracellular calcium ion and cyclic GMP levels
through bradykinin B2 receptors and induces a rapid and transient
elevation in the paracellular transport of 5 kDa inulin in cultured brain
endothelial cells [68,239]. Cereport opened brain endothelial TJs [240]
and enhanced the CNS delivery of carboplatin, loperamide and
cyclosporin-A [205–208] (Table 5). Cereport attached to liposomes
facilitated Evans blue penetration to brain in rats [241]. Enhanced tumour
uptake of chemotherapeutics and increased survival were found in
Cereport-treated animals using rodent models of glioma and metastatic
brain tumours [207,208]. After promising preclinical trials and Phase I
studies, no beneﬁt of Cereport was found in a Phase II study in childhood
high-grade and brainstem gliomas [209]. Despite the failure of Cereport
to potentiate chemotherapy of brain tumours, where high level of Pgp on
the tumour cells restricts the efﬁcacy of chemotherapy, Cereport can still
be useful in enhancing drug delivery across BBB [205–208,241].
Histamine decreases TEER and increases the permeability for
paracellular markers in BBB models in vitro [66] and in vivo [235].
Small dose of histamine injected to the carotid artery resulted in a
selective extravasation of Evans blue and an increase in the transport
of γ-aminoisobutyric acid in the brain tumour without changing BBB
permeability in other regions [210,211]. The signalling pathway
involves histamine H2 receptors, NO and cyclic GMP production
[242,243]. A reversible and concentration-dependent reduction in TJ
protein ZO-1 was observed in histamine-treated retinal endothelial
cells, which show similar properties to BBB [244].
6.2. Permeability enhancers and new experimental approaches
Calcium and other divalent cations are needed for the integrity of
brain endothelial TJs, similarly to epithelial cells. Removal of
extracellular calcium ions by chelators BAPTA and EGTA (Table 5)
results in a rapid opening of TJs in brain endothelial cells, a decrease in
TEER, and an increase in sucrose ﬂux [66]. However, chelators have not
been tested for drug delivery to brain in cell culture or animal studies.Fatty acids and modiﬁed fatty acids are effective absorption
enhancers in epithelial barriers, and some of them have been also
tested on the BBB. Reversible opening of the BBB to Evans blue and γ-
aminoisobutyric acid was observed after intracarotid artery infusion
of oleic acid in rats [181]. Since oleic acid is a PKC activator, an effect on
signalling pathways regulating TJs should be considered. Emulsions
made from oleic acid or linoleic acid injected to carotid artery of cats
increased BBB permeability in a reversible manner detected by
magnetic resonance imaging (MRI) [182]. Sodium caprate, a clinically
used AE in the GI tract, when given as intracarotid infusion pro-
duced reversible, dose-related BBB opening for mannitol in rats
[213] (Table 5). However, high doses were toxic and caused severe
brain edema and cardio-respiratory failure [213].
The phospholipid LPA, found in animal sera used for cell cultures or
released in high amount during subarachnoid haemorrhage, causes a
rapid, reversible and dose-dependent decrease in TEER in brain
endothelial cells [163,245]. The barrier weakening was accompanied
by redistribution of occludin, claudin-5 and ZO-1 indicating that TJ
proteins are directly affected by LPA-treatment [245].
The anionic surfactant SDS, widely used as solubilizer and stabilizer in
pharmaceutical preparations, and a known AE, elicited an extensive, dose-
dependent and reversible BBB opening in rats [214]. Intracarotid infusion of
SDS caused Evans blue extravasation, and a signiﬁcant increase in γ-
aminoisobutyric acid transport to brain. Part of the effect is hypothesized to
bemediated by TJmodulation [214]. The ionic surfactant bile salts, effective
as AE in the GI tract also induce reversible BBB opening. Sodium
dehydrocholate infusion to the carotid artery of rats disrupted the BBB for
ﬂuorescein andEvans blue in a concentration-dependentmanner [215,216].
Sodium deoxycholate and taurochenodeoxycholate had the same effect
when tested using in situ rat brain perfusion [217]. A modiﬁed bile salt,
sodium dihydroxy-oxo-cholanate, enhanced BBB permeability for quinine,
morphine and pentobarbital in rats, but its action on brain endothelial TJs is
unspeciﬁed [218]. Because dehydrocholate and deoxycholate are strong
detergents at highdoses, and lytic actiononendothelial cellmembranes can
beobservedwith thedevelopmentof EEGchanges andepileptiformactivity
[217,246,247], their possible clinical application is limited.
The negative surface charge of the luminal endothelial membrane
of brain vessels contributes to the barrier phenotype and cationic
molecules show better BBB permeability (for review see [66]).
Intracarotid infusion of polycations protamine, poly-L-lysine and
poly-L-arginine in rats resulted in permeability increase for albumin
[219]. In a rat brain perfusionmodel protamine decreased the negative
luminal surface charge in brain vessels and increased the extravasa-
tion of HRP by opening endothelial TJs [167]. The cationic polymer
chitosan applied in microemulsion could improve nobiletin transport
to brain inmicewhen given intravenously [220], although themode of
action or speciﬁc effects on TJs have not been investigated.
Native α-CD- and β-CD-treatment causes a rapid increase in
sucrose permeability of brain endothelial monolayers in parallel with
their ability to extract phospholipids and cholesterol from the cell
membranes [172]. Hydroxypropyl-γ-CD and γ-CD at high concentra-
tion increased doxorubicin transport across brain endothelial mono-
layers parallelly with the loss of BBB integrity and decreased
junctional staining of occludin [173]. Rame-β-CD and chrisme-β-CD
were also able to enhance doxorubicin transport in the same in vitro
BBB model (Table 5), and this effect correlated to the cholesterol
extracting capacity of β-CDs, which maymodulate TJs and the activity
of efﬂux pumps in the brain endothelial cell membranes [221].
While basal NOproduction is necessary for the BBB integrity, excessive
NO release either by inducible NO synthase or by NO donors leads to
increased permeability in BBB models [66]. NO donor molecule SNAP
enhanced the BBB sucrose permeability about 5-fold in all forebrain
regions using an in situ rodent brain perfusion method [222]. Intracarotid
infusion of diethylammonium (Z)-1-(N,N-diethylamino)diazen-1-ium
1,2-diolate (DEA-NONOate) and (Z)-1-[N-(2-aminopropyl)-N-(2-ammo-
nio propyl)amino]diazen-1-ium 1,2-diolate (PAPA-NONOate), short-
905M.A. Deli / Biochimica et Biophysica Acta 1788 (2009) 892–910actingNOdonors, in RG2 tumour bearing rats led to increased transport of
γ-aminoisobutyric acid to the tumour tissue [174] (Table 5). The effect of
DEA-NONOate and PAPA-NONOate on brain tumour vessel permeability
was mediated by calcium-activated potassium channels [174] (Table 4).
Osmotic stress induced bymannitol or arabinose causes a rapid and
reversible decrease in TEER, and increases permeability for paracel-
lularmarkers sucrose and inulin through brain endothelialmonolayers
[66], and in animal models (for review see [248]). After intracarotid
infusion of hyperosmotic arabinose dilatation of junctional clefts and
changes in the localization and expression of TJ proteins occludin,
claudin-5, JAM-1 and ZO-1 were observed in rats [224]. Src kinase
mediated phosphorylation of AJ protein β-catenin may play a role in
the mechanism of mannitol-induced TJ opening [175]. Ongoing
multicenter clinical studies suggest that BBB disruption by intraarterial
hyperosmotic mannitol can enhance the penetration of anticancer
drugs and prolong survival in patients with malignant brain tumours
[226] (Table 5). Despite successful application in some centers, the
method has not beenwidely spread, because the procedure is difﬁcult,
invasive, and posttreatment neurotoxicity may develop.
Erdlenbruch et al. demonstrated, that the short chain alkylglycerol,
1-O-pentylglycerol, given to the carotid artery could rapidly and
reversibly enhance the ipsilateral brain penetration of antineoplastic
agents cisplatin andmethotrexate and the antibiotics vancomycin and
gentamycin in rats [249]. It also enhanced the delivery of erucylpho-
sphocholine and methotrexate to rat C6 and RG2 implanted tumours
[227,228,249,250]. 1-O-pentylglycerol induced the extravasation of
ﬂuorescein, albumin and methotrexate in the ipsilateral brain and to
the tumour by enhancing paracellular permeability of TJs [228]. The
effect of 1-O-pentylglycerol was lower than that of hyperosmotic
mannitol, and much higher than the effect of bradykinin, but in
contrast to mannitol it did not enhance BBB permeability in the
contralateral brain hemisphere or the cerebellum and brain stem
[227]. The effect and duration of alkylglycerol-induced BBB-opening
was more rapid and localized to the site of injection, with less in vivo
toxicity [227], offering a newand safer alternative of BBB disruption by
hyperosmotic mannitol.
There are a growing number of papers describing experimental
BBB opening by high intensity focused ultrasound (for review see
[251]). Low frequency MRI-guided ultrasound bursts could induce
local, reversible disruption of BBB in rabbits [229] and increase the
brain delivery of dopamine D4 receptor antibody, and a humanized
anti-human epidermal growth factor receptor 2 monoclonal antibody,
Herceptin, in mice [230,231], and doxorubicin in rats [232] (Table 5).
The method is not speciﬁc to TJs, the mechanisms of transport of
molecules by sonication can involve transcytosis, endothelial fenes-
tration and channel formation, partial opening of TJs and free passage
through injured endothelium [252]. If the method will be proved safe
and effective in more experimental models, MRI-guided focused
ultrasound may have a great potential to treat CNS malignancies
[226].
Although the 0.02 m2 surface area of the blood-cerebrospinal ﬂuid
barrier created by the choroid plexus is negligible compared to the
surface area of the BBB, it plays an important role in the regulation of
drug transport and metabolism in the CNS [253,254]. Blood vessels in
the choroid plexus are leaky, and the barrier is formed by epithelial
cells expressing TJ proteins occludin, claudin-1, -2, -5, -11, ZO-1
[255,256]. Modulation of TJ permeability in choroid plexus epithelium
and at the BBB shows similarities. The barrier permeability is
increased by cyclic AMP [257], and decreased by phorbol ester-
induced activation of PKC both in vitro and in vivo [255,258,259]. The
PKC-mediated permeabilization of epithelial cells is accompanied by
dephosphorylation and reduced immunostaining of occludin, down-
regulation of claudin-2, decreased immunoreactivity for claudin-2, -5,
cadherin and β-catenin [255,258]. Modulation of TJs at the level of the
choroid plexus might provide an additional route for drug delivery to
the CNS.7. Concluding remarks
In contrast to strategies targeting transepithelial/transendothelial
pathways, modulators acting on TJs could enhance paracellular
permeability of biological barriers for a large number and variety of
drugs, including hydrophylic compounds, biopharmaceuticals, like
peptides, proteins, nucleic acids, and viral vectors without the need to
modify the drugs. The concept is proven by the clinical application of
several AEs, like sodium caprate, cyclodextrins or oleic acid, which act,
at least partly, through modiﬁcation of epithelial tight junctions.
Because of the low selectivity and relatively high toxicity of AEs there
is a need for new TJ modulators.
Intense research in several laboratories to develop safe and
effective TJ modulators will result in increasing number of new
peptides speciﬁc for unique TJ proteins with better organ or region
selectivity and lower toxicity in the near future. For example, the
selectivity of C-CPE peptide targeting claudin-4 and acting in the
jejunum, but not in colon, seems to be promising [117]. Targeting
claudin-5, or claudin-1 could lead to TJ modulators selective for the
BBB or for the skin.
Beside peptides, antibodies, antibody fragments and small inter-
fering nucleic acids speciﬁc for TJ proteins could also be potential
modulators of paracellular permeability. While signalling pathways
regulating TJs look promising targets of chemical compound mod-
ulators, like kinase inhibitors, they are far from being clinically
applicable. The organ or tissue selectivity and the safety of these
molecules have to be ﬁrst proven.
Opening of TJs for a drug molecule might result in the enhanced
transport of other molecules, xenobiotics or pathogens across the
protective barriers of the GI tract, the BBB or the airways. TJs and their
components play a fundamental role in morphogenesis and cell
polarity. Safety assessment of TJ modulators should include careful
testing and analysis for global adverse drug reactions, enhanced
sensitivity for bacterial or viral infections, and long-term carcinogenic
or teratogenic effects.
Some of the new TJ modulators have already entered clinical trials.
AT1001 (Table 2), a TJ modulator to decrease intestinal hyperperme-
ability, has been tested for safety and efﬁcacy to treat celiac disease
[260]. The effect of the permeability enhancer PN-159 is being
examined in Phase II studies on nasal insulin and peptide YY3–36
administration to control type 2 diabetes and induce weight loss in
obesity, respectively [261].
As a conclusion, the number of TJ modulators with a potential to be
used in drug delivery is expected to greatly increase in the near future
and provide an unprecedented selectivity for various barriers, as well
as better efﬁcacy and safety.
Acknowledgements
This work was supported by grants from the National Ofﬁce for
Research and Technology (RET 08/2004) and the Hungarian Ministry
of Health ETT 589/2006. The help of Dr. Csongor Ábrahám for critical
reading of the manuscript is gratefully acknowledged.References
[1] L. González-Mariscal, P. Nava, Tight junctions, from tight intercellular seals to
sophisticated protein complexes involved in drug delivery, pathogens interac-
tion and cell proliferation, Adv. Drug Deliv. Rev. 57 (2005) 811–814.
[2] H. Chiba, M. Osanai, M. Murata, T. Kojima, N. Sawada, Transmembrane proteins of
tight junctions, Biochim. Biophys. Acta 1778 (2008) 729–756.
[3] L. González-Mariscal, R. Tapia, D. Chamorro, Crosstalk of tight junction
components with signalling pathways, Biochim. Biophys. Acta 1778 (2008)
729–756.
[4] M. Takano, R. Yumoto, T. Murakami, Expression and function of efﬂux drug
transporters in the intestine, Pharmacol. Ther. 109 (2006) 137–161.
[5] N.J. Abbott, L. Rönnback, E. Hansson, Astrocyte-endothelial interactions at the
blood–brain barrier, Nat. Rev. Neurosci. 7 (2006) 41–53.
906 M.A. Deli / Biochimica et Biophysica Acta 1788 (2009) 892–910[6] R.S. El-Bacha, A. Minn, Drug metabolizing enzymes in cerebrovascular
endothelial cells afford a metabolic protection to the brain, Cell. Mol. Biol. 45
(1999) 15–23 (Noisy-le-grand).
[7] P.D. Ward, T.K. Tippin, D.R. Thakker, Enhancing paracellular permeability by
modulating epithelial tight junctions, Pharm. Sci. Technol. Today 3 (2000)
346–358.
[8] Y. Masaoka, Y. Tanaka, M. Kataoka, S. Sakuma, S. Yamashita, Site of drug
absorption after oral administration: assessment of membrane permeability and
luminal concentration of drugs in each segment of gastrointestinal tract, Eur. J.
Pharm. Sci. 29 (2006) 240–250.
[9] G. Scheuch, M.J. Kohlhaeuﬂ, P. Brand, R. Siekmeier, Clinical perspectives on
pulmonary systemic and macromolecular delivery, Adv. Drug Deliv. Rev. 58
(2006) 996–1008.
[10] A. Naik, Y.N. Kalia, R.H. Guy, Transdermal drug delivery: overcoming the skin's
barrier function, Pharm. Sci. Technol. Today 3 (2000) 318–326.
[11] R. Cecchelli, V. Berezowski, S. Lundquist, M. Culot, M. Renftel, M.-P. Dehouck, L.
Fénart, Modelling of the blood–brain barrier in drug discovery and development,
Nat. Rev. Drug Discov. 6 (2007) 650–661.
[12] H.Wolburg, A. Lippoldt, Tight junctions of the blood–brain barrier: development,
composition and regulation, Vasc. Pharmacol. 38 (2002) 323–337.
[13] N.J. Abbott, Astrocyte-endothelial interactions and blood–brain barrier perme-
ability, J. Anat. 200 (2002) 629–638.
[14] W.M. Pardridge, Drug and gene targeting to brain with molecular Trojan horses,
Nat. Rev. Drug Discov. 1 (2002) 131–139.
[15] E. Neuwelt, N.J. Abbott, L. Abrey, W.A. Banks, B. Blakley, T. Davis, B. Engelhardt, P.
Grammas, M. Nedergaard, J. Nutt, W. Pardridge, G.A. Rosenberg, Q. Smith, L.R.
Drewes, Strategies to advance translational research into brain barriers, Lancet
Neurol. 7 (2008) 84–96.
[16] L. Illum, Nasal drug delivery-possibilities, problems and solutions, J. Control.
Release 87 (2003) 187–198.
[17] H. Wolburg, K. Wolburg-Buchholz, H. Sam, S. Horvát, M.A. Deli, A.F. Mack,
Epithelial and endothelial barriers in the olfactory region of the nasal cavity of
the rat, Histochem. Cell Biol. 130 (2008) 127–140.
[18] L. Illum, Nasal drug delivery: new developments and strategies, Drug Discov.
Today 7 (2002) 1184–1189.
[19] M. Abdulrazik, S. Tamilvanan, S. Benita, Non-systemic delivery of topical
brimonidine to the brain: a neuro-ocular tissue distribution study, J. Drug
Target. 15 (2006) 670–679.
[20] A. Lambiase, L. Pagani, V. Di Fausto, V. Sposato, M. Coassin, S. Bonini, L. Aloe,
Nerve growth factor eye drop administrated on the ocular surface of rodents
affects the nucleus basalis and septum: biochemical and structural evidence,
Brain Res. 1127 (2007) 45–51.
[21] G. Krause, L. Winkler, S.L. Mueller, R.F. Haseloff, J. Piontek, I.E. Blasig, Structure
and function of claudins, Biochim. Biophys. Acta 1778 (2008) 631–645.
[22] L. Paris, L. Tonutti, C. Vannini, G. Bazzoni, Structural organization of the tight
junctions, Biochim. Biophys. Acta 1778 (2008) 646–659.
[23] A.W. Vorbrodt, D.H. Dobrogowska, Molecular anatomy of interendothelial
junctions in human blood–brain barrier microvessels, Folia Histochem. Cytobiol.
42 (2004) 67–75.
[24] A. Nusrat, C.A. Parkos, P. Verkade, C.S. Foley, T.W. Liang, W. Innis-Whitehouse, K.
K. Eastburn, J.L. Madara, Tight junctions are membrane microdomains, J. Cell Sci.
113 (2000) 1771–1781.
[25] M. Furuse, T. Hirase, M. Itoh, A. Nagafuchi, S. Yonemura, S. Tsukita, S. Tsukita,
Occludin: a novel integral membrane protein localizing at tight junctions, J. Cell
Biol. 123 (1993) 1777–1788.
[26] M. Saitou, M. Furuse, H. Sasaki, J.D. Schulzke, M. Fromm, H. Takano, T. Noda, S.
Tsukita, Complex phenotype of mice lacking occludin, a component of tight
junction strands, Mol. Biol. Cell 11 (2000) 4131–4142.
[27] D. Yu, J.R. Turner, Stimulus-induced reorganization of tight junction structure:
the role of membrane trafﬁc, Biochim. Biophys. Acta 1778 (2008) 709–716.
[28] J. Ikenouchi, M. Furuse, K. Furuse, H. Sasaki, S. Tsukita, S. Tsukita, Tricellulin
constitutes a novel barrier at tricellular contacts of epithelial cells, J. Cell Biol. 171
(2005) 939–945.
[29] S. Riazuddin, Z.M. Ahmed, A.S. Fanning, A. Lagziel, S. Kitajiri, K. Ramzan, S.N.
Khan, P. Chattaraj, P.L. Friedman, J.M. Anderson, I.A. Belyantseva, A. Forge, S.
Riazuddin, T.B. Friedman, Tricellulin is a tight-junction protein necessary for
hearing, Am. J. Hum. Genet. 79 (2006) 1040–1051.
[30] T.A. Martin, Loss of barrier function and its role in cancer metastasis, Biochim.
Biophys. Acta (2008-this issue).
[31] V. Tasic, D. Dervisov, S. Koceva, S. Weber, M. Konrad, Hypomagnesemia with
hypercalciuria and nephrocalcinosis: case report and a family study, Pediatr.
Nephrol. 20 (2005) 1003–1006.
[32] M. Konrad, A. Schaller, D. Seelow, A.V. Pandey, S. Waldegger, A. Lesslauer, H.
Vitzthum, Y. Suzuki, J.M. Luk, C. Becker, K.P. Schlingmann, M. Schmid, J.
Rodriguez-Soriano, G. Ariceta, F. Cano, R. Enriquez, H. Juppner, S.A. Bakkaloglu,
M.A. Hediger, S. Gallati, S.C. Neuhauss, P. Nurnberg, S. Weber, Mutations in the
tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium
wasting, renal failure, and severe ocular involvement, Am. J. Hum. Genet. 79
(2006) 949–957.
[33] J.H. Lipschutz, S. Li, A. Arisco, D.F. Balkovetz, Extracellular signal-regulated
kinases 1/2 control claudin-2 expression in Madin–Darby canine kidney strain I
and II cells, J. Biol. Chem. 280 (2005) 3780–3788.
[34] M. Furuse, M. Hata, K. Furuse, Y. Yoshida, A. Haratake, Y. Sugitani, T. Noda, A.
Kubo, S. Tsukita, Claudin-based tight junctions are crucial for the mammalian
epidermal barrier: a lesson from claudin-1 deﬁcient mice, J. Cell Biol. 156 (2002)
1099–1111.[35] K.M. McCarthy, I.B. Skare, M.C. Stankewich, M. Furuse, S. Tsukita, R.A. Rogers, R.D.
Lynch, E.E. Schneeberger, Occludin is a functional component of the tight
junction, J. Cell Sci. 109 (1996) 2287–2298.
[36] A. Tamura, Y. Kitano, M. Hata, T. Katsuno, K. Moriwaki, H. Sasaki, H. Hayashi, Y.
Suzuki, T. Noda, M. Furuse, S. Tsukita, S. Tsukita, Megaintestine in claudin-15-
deﬁcient mice, Gastroenterology 134 (2008) 523–534.
[37] T. Nitta, M. Hata, S. Gotoh, Y. Seo, H. Sasaki, N. Hashimoto, M. Furuse, S. Tsukita,
Size-selective loosening of the blood–brain barrier in claudin-5-deﬁcient mice,
J. Cell Biol. 161 (2003) 653–660.
[38] K. Hirata, T. Ishida, K. Penta, M. Rezaee, E. Yang, J. Wohlgemuth, T. Quertermous,
Cloning of an immunoglobulin family adhesion molecule selectively expressed
by endothelial cells, J. Biol. Chem. 276 (2001) 16223–16231.
[39] W.M. Pardridge, Blood–brain barrier genomics, Stroke 38 (Suppl 2) (2007)
686–690.
[40] F. Wegmann, B. Petri, A.G. Khandoga, C. Moser, A. Khandoga, S. Volkery, H. Li, I.
Nasdala, O. Brandau, R. Fässler, S. Butz, F. Krombach, D. Vestweber, ESAM
supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular
permeability, J. Exp. Med. 203 (2006) 1671–1677.
[41] B.B. Finlay, Tight junction proteins as targets of infectious agents, Biochim.
Biophys. Acta (2008-this issue).
[42] M. Kondoh, A. Takahashi, M. Fuji, K. Yagi, Y. Watanabe, A novel strategy for a
drug delivery system using a claudin modulator, Biol. Pharm. Bull. 29 (2006)
1783–1789.
[43] M. Kondoh, K. Yagi, Tight junction modulators: promising candidates for drug
delivery, Curr. Med. Chem. 14 (2007) 2482–2488.
[44] A. Hartsock, W.J. Nelson, Adherens and tight junctions: structure, function and,
connections to the actin cytoskeleton, Biochim. Biophys. Acta 1778 (2008)
660–669.
[45] D. Pal, K.L. Audus, T.J. Siahaan, Modulation of cellular adhesion in bovine brain
microvessel endothelial cells by a decapeptide, Brain Res. 747 (1997) 103–113.
[46] J.M. Halbleib, W.J. Nelson, Cadherins in development: cell adhesion, sorting, and
tissue morphogenesis, Genes Dev. 20 (2006) 3199–3214.
[47] J.A. Tunggal, I. Helfrich, A. Schmitz, H. Schwarz, D. Gunzel, M. Fromm, R. Kemler,
T. Krieg, C.M. Niessen, E-cadherin is essential for in vivo epidermal barrier
function by regulating tight junctions, EMBO J. 24 (2005) 1146–1156.
[48] J. Zabner, M. Winter, K.J. Excoffon, D. Stoltz, D. Ries, S. Shasby, M. Shasby,
Histamine alters E-cadherin cell adhesion to increase human airway epithelial
permeability, J. Appl. Physiol. 95 (2003) 394–401.
[49] M. Conacci-Sorrell, J. Zhurinsky, A. Ben-Ze'ev, The cadherin–catenin adhesion
system in signaling and cancer, J. Clin. Invest. 109 (2002) 987–991.
[50] E. Dejana, M.G. Lampugnani, O. Martinez-Estrada, G. Bazzoni, The molecular
organization of endothelial junctions and their functional role in vascular
morphogenesis and permeability, Int. J. Dev. Biol. 44 (2000) 743–748.
[51] M.T. Broman, D. Mehta, A.B. Malik, Cdc42 regulates the restoration of endothelial
adherens junctions and permeability, Trends Cardiovasc. Med. 17 (2007)
151–156.
[52] J. Gavard, J.S. Gutkind, VEGF controls endothelial-cell permeability by promoting
the beta-arrestin-dependent endocytosis of VE-cadherin, Nat. Cell Biol. 8 (2006)
1223–1234.
[53] C.M. Niessen, Tight junctions/adherens junctions: basic structure and function,
J. Invest. Dermatol. 127 (2007) 2525–2532.
[54] K. Irie, K. Shimizu, T. Sakisaka, W. Ikeda, Y. Takai, Roles and modes of action of
nectins in cell–cell adhesion, Semin. Cell Dev. Biol. 15 (2004) 643–656.
[55] S. Fabre-Lafay, F. Monville, S. Garrido-Urbani, C. Berruyer-Pouyet, C. Ginestier, N.
Reymond, P. Finetti, R. Sauvan, J. Adélaïde, J. Geneix, E. Lecocq, C. Popovici, P.
Dubreuil, P. Viens, A. Gonçalves, E. Charafe-Jauffret, J. Jacquemier, D. Birnbaum,
M. Lopez, Nectin-4 is a new histological and serological tumor associatedmarker
for breast cancer, BMC Cancer 7 (2007) 73.
[56] A.R. Schenkel, T.W. Chew, W.A. Muller, Platelet endothelial cell adhesion
molecule deﬁciency or blockade signiﬁcantly reduces leukocyte emigration in
a majority of mouse strains, J. Immunol. 173 (2004) 6403–6408.
[57] Z. Sun, K. Olanders, A. Lasson, M. Dib, M. Annborn, K. Andersson, X. Wang, R.
Andersson, Effective treatment of gut barrier dysfunction using an antioxidant,
a PAF inhibitor, and monoclonal antibodies against the adhesion molecule
PECAM-1, J. Surg. Res. 105 (2002) 220–233.
[58] J.P. Couty, C. Rampon, M. Leveque, M.P. Laran-Chich, S. Bourdoulous, J. Greenwood,
P.O. Couraud, PECAM-1 engagement counteracts ICAM-1-induced signaling in
brain vascular endothelial cells, J. Neurochem. 103 (2007) 793–801.
[59] M. Pentecost, G. Otto, J.A. Theriot, M.R. Amieva, Listeria monocytogenes invades
the epithelial junctions at sites of cell extrusion, PLoS Pathogens 2 (2006) 29–40.
[60] Z. Yu, S. Li, Y.Y. Huang, Y. Fong, R.J. Wong, Calcium depletion enhances nectin-1
expression and herpes oncolytic therapy of squamous cell carcinoma, Cancer
Gene Ther. 14 (2007) 738–747.
[61] K. Matter, M.S. Balda, Functional analysis of tight junctions, Methods 30 (2003)
228–234.
[62] I.A. Krizbai, M.A. Deli, Signalling pathways regulating the tight junction
permeability in the blood–brain barrier, Cell. Mol. Biol. 49 (2003) 23–31
(Noisy-Le-Grand).
[63] H. Clarke, N. Ginanni, K.V. Laughlin, J.B. Smith, G.R. Pettit, J.M. Mullin, The
transient increase of tight junction permeability can result from protein kinase C
activation/translocation and act as a tumor promotional event in epithelial
cancers, Exp. Cell Res. 261 (2000) 239–249.
[64] M.A. Deli, M.P. Dehouck, C.S. Ábrahám, R. Cecchelli, F. Joó, Penetration of small
molecular weight substances through cultured bovine brain capillary endothelial
cell monolayers: the early effects of 3′,5′-cyclic adenosine monophosphate, Exp.
Physiol. 80 (1995) 675–678.
907M.A. Deli / Biochimica et Biophysica Acta 1788 (2009) 892–910[65] B. Kis, M.A. Deli, H. Kobayashi, C.S. Ábrahám, T. Yanagita, H. Kaiya, T. Isse, R. Nishi,
S. Gotoh, K. Kangawa, A. Wada, J. Greenwood, M. Niwa, H. Yamashita, Y. Ueta,
Adrenomedullin regulates blood–brain barrier functions in vitro, Neuroreport 12
(2001) 4139–4142.
[66] M.A. Deli, C.S. Ábrahám, Y. Kataoka, M. Niwa, Permeability studies on in vitro
blood–brain barrier models: physiology, pathology and pharmacology, Cell. Mol.
Neurobiol. 25 (2005) 59–127.
[67] M. Honda, S. Nakagawa, K. Hayashi, N. Kitagawa, K. Tsutsumi, I. Nagata, M. Niwa,
Adrenomedullin improves the blood–brain barrier function through the
expression of claudin-5, Cell. Mol. Neurobiol. 26 (2006) 109–118.
[68] J.B. Mackic, M. Stins, S. Jovanovic, K.S. Kim, R.T. Bartus, B.V. Zlokovic, Cereport
(RMP-7) increases the permeability of human brain microvascular endothelial
cell monolayers, Pharm. Res. 16 (1999) 1360–1365.
[69] T. Hirase, S. Kawashima, E.Y. Wong, T. Ueyama, Y. Rikitake, S. Tsukita, M.
Yokoyama, J.M. Staddon, Regulation of tight junction permeability and occludin
phosphorylation by RhoA-p160ROCK-dependent and -independent mechan-
isms, J. Biol. Chem. 276 (2001) 10423–10431.
[70] K. Umeda, J. Ikenouchi, S. Katahira-Tayama, K. Furuse, H. Sasaki, M. Nakayama, T.
Matsui, S. Tsukita, M. Furuse, S. Tsukita, ZO-1 and ZO-2 independently determine
where claudins are polymerized in tight-junction strand formation, Cell 126
(2006) 741–754.
[71] M. Bruewer, A.M. Hopkins, M.E. Hobert, A. Nusrat, J.L. Madara, RhoA, Rac1, and
Cdc42 exert distinct effects on epithelial barrier via selective structural and
biochemical modulation of junctional proteins and F-actin, Am. J. Physiol. Cell
Physiol. 287 (2004) C327–C335.
[72] G. Schreibelt, G. Kooij, A. Reijerkerk, R. van Doorn, S.I. Gringhuis, S. van der Pol,
B.B. Weksler, I.A. Romero, P.O. Couraud, J. Piontek, I.E. Blasig, C.D. Dijkstra, E.
Ronken, H.E. de Vries, Reactive oxygen species alter brain endothelial tight
junction dynamics via RhoA, PI3 kinase, and PKB signaling, FASEB J. 21 (2007)
3666–3676.
[73] O.N. El-Assal, G.E. Besner, HB-EGF enhances restitution after intestinal ischemia/
reperfusion via PI3K/Akt and MEK/ERK1/2 activation, Gastroenterology 129
(2005) 609–625.
[74] S. Fischer, M. Wiesnet, D. Renz, W. Schaper, H2O2 induces paracellular
permeability of porcine brain-derived microvascular endothelial cells by
activation of the p44/42 MAP kinase pathway, Eur. J. Cell Biol. 84 (2005)
687–697.
[75] C. Vogel, A. Bauer, M. Wiesnet, K.T. Preissner, W. Schaper, H.H. Marti, S. Fischer,
Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/
Akt pathway, J. Cell. Physiol. 212 (2007) 236–243.
[76] D. Langford, R. Hurford, M. Hashimoto, M. Digicaylioglu, E. Masliah, Signalling
crosstalk in FGF2-mediated protection of endothelial cells from HIV-gp120, BMC
Neurosci. 6 (2005) 8.
[77] I.E. András, H. Pu, J. Tian, M.A. Deli, A. Nath, B. Hennig, M. Toborek, Signaling
mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain
endothelial cells, J. Cereb. Blood Flow Metab. 25 (2005) 1159–1170.
[78] K. Grebenkämper, H.J. Galla, Translational diffusion measurements of a
ﬂuorescent phospholipid between MDCK-I cells support the lipid model of the
tight junctions, Chem. Phys. Lipids 71 (1994) 133–143.
[79] C.A. Feltkamp, A.W. Van der Waerden, Junction formation between cultured
normal rat hepatocytes. An ultrastructural study on the presence of cholesterol
and the structure of developing tight-junction strands, J. Cell. Sci. 63 (1983)
271–286.
[80] M.C. Stankewich, S.A. Francis, Q.U. Vu, E.E. Schneeberger, R.D. Lynch, Alterations
in cell cholesterol content modulate Ca2+-induced tight junction assembly by
MDCK cells, Lipids 31 (1996) 817–828.
[81] D. Lambert, C.A. O'Neill, P.J. Padﬁeld, Methyl-beta-cyclodextrin increases
permeability of Caco-2 cell monolayers by displacing speciﬁc claudins from
cholesterol rich domains associated with tight junctions, Cell. Physiol. Biochem.
20 (2007) 495–506.
[82] S.A. Francis, J.M. Kelly, J. McCormack, R.A. Rogers, J. Lai, E.E. Schneeberger, R.D.
Lynch, Rapid reduction of MDCK cell cholesterol by methyl-β-cyclodextrin alters
steady-state transepithelial electrical resistance, Eur. J. Cell Biol. 78 (1999)
473–484.
[83] P.H. Johnson, S.C. Quay, Advances in nasal drug delivery through tight junction
technology, Expert Opin. Drug Deliv. 2 (2005) 281–298.
[84] M. Kondoh, T. Yoshida, H. Kakutani, K. Yagi, Targeting tight junction proteins —
signiﬁcance for drug development, Drug Discov. Today 13 (2008) 180–186.
[85] P.H. Johnson, D. Frank, H.R. Constantino, Discovery of tight junction modulators:
signiﬁcance for drug development and therapy, Drug Discov. Today 13 (2008)
261–267.
[86] V. Wong, B. Gumbiner, A synthetic peptide corresponding to the extracellular
domain of occludin perturbs the tight junction permeability barrier, J. Cell Biol.
136 (1997) 399–409.
[87] F. Lacaz-Vieira, M.M. Jaeger, P. Farshori, B. Kachar, Small synthetic peptides
homologous to segments of the ﬁrst external loop of occludin impair tight
junction resealing, J. Membr. Biol. 168 (1999) 289–297.
[88] S. Tavelin, K. Hashimoto, J. Malkinson, L. Lazorova, I. Toth, P. Artursson, A new
principle for tight junction modulation based on occludin peptides, Mol.
Pharmacol. 64 (2003) 1530–1540.
[89] R.S. Everett, M.K. Vanhook, N. Barozzi, I. Toth, L.G. Johnson, Speciﬁc modulation
of airway epithelial tight junctions by apical application of an occludin peptide,
Mol. Pharmacol. 69 (2006) 492–500.
[90] C.H. Wong, D.D. Mruk, W.M. Lee, C.Y. Cheng, Targeted and reversible disruption
of the blood–testis barrier by an FSH mutant-occludin peptide conjugate, FASEB
J. 21 (2007) 438–448.[91] S.C. Quay, Composition for enhaced epithelial permeation of peptide YY for
treating obesity, United States patent Application, Pub. No.: US 2007/0275893
A1 (2007).
[92] H. Wan, H.L. Winton, C. Soeller, D.C. Gruenert, P.I. Thompson, M.B. Cannell,
G.A. Stewart, D.R. Garrod, C. Robinson, Quantitative structural and
biochemical analyses of tight junction dynamics following exposure of
epithelial cells to house dust mite allergen Der p 1, Clin. Exp. Allergy 30
(2000) 685–698.
[93] D.J. O'Mahony, G. Cagney, Composition and method for enhancing paracellular
transport across cell layers, United States Patent, Patent No.: US 6,346,613 B1
(2002).
[94] K. Cui, B.H. Dutzar, Method for opening tight junctions, United States Patent
Application, Pub. No.: US 2007/0253956 A1 (2007).
[95] N. Sonoda, M. Furuse, H. Sasaki, S. Yonemura, J. Katahira, Y. Horiguchi, S. Tsukita,
Clostridium perfringens enterotoxin fragment removes speciﬁc claudins from
tight junction strands: evidence for direct involvement of claudins in tight
junction barrier, J. Cell Biol. 147 (1999) 195–204.
[96] T.A. Bird, A. Youakim, Claudin polypeptides, polynucleotides, and methods of
making and use thereof, United States Patent Application Publication, Pub. No.:
US 2008/0009004 (2008).
[97] E. Sinaga, D.S.S. Jois, M. Avery, I.T. Makagiansar, U.S.F. Tambunan, K.L. Audus, T.J.
Siahaan, Increasing paracellular porosity by E-cadherin peptides: discovery of
bulge and groove regions in the EC1-domain of E-cadherin, Pharm. Res. 19
(2002) 1170–1179.
[98] A. Fasano, B. Baudry, D.W. Pumplin, S.S. Wasserman, B.D. Tall, J.M. Ketley, J.B.
Kaper, Vibrio cholerae produces a second enterotoxin, which affects intestinal
tight junctions, Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 5242–5246.
[99] A. Fasano, C. Fiorentini, G. Donelli, S. Uzzau, J.B. Kaper, K. Margaretten, X. Ding, S.
Guandalini, L. Comstock, S.E. Goldblum, Zonula occludens toxin modulates tight
junctions through protein kinase C-dependent actin reorganization, in vitro,
J. Clin. Invest. 96 (1995) 710–720.
[100] A. Fasano, S. Uzzau, Modulation of intestinal tight junctions by zonula occludens
toxin permits enteral administration of insulin and other macromolecules in an
animal model, J. Clin. Invest. 99 (1997) 1158–1164.
[101] M. DiPierro, R. Lu, S. Uzzau, W. Wang, K. Margaretten, C. Pazzani, F. Maimone, A.
Fasano, Zonula occludens toxin structure–function analysis. Identiﬁcation of the
fragment biologically active on tight junctions and of the zonulin receptor
binding domain, J. Biol. Chem. 276 (2001) 19160–19165.
[102] T. Watts, I. Berti, A. Sapone, T. Gerarduzzi, T. Not, R. Zielke, A. Fasano, Role of the
intestinal tight junction modulator zonulin in the pathogenesis of type 1
diabetes in BB diabetic-prone rats, Proc. Natl. Acad. Sci. U. S. A. 102 (2005)
2916–2921.
[103] A. Fasano, B. Paterson, Use of tight junction agonists to facilitate pulmonary
delivery of therapeutic agents, United States Patent Application, Pub. No.: US
2008/0014218 A1 (2008).
[104] K. Cui, S.-C. Chen, M.E. Houston, S.C. Quay, Tight junction modulator peptide
PN159 for enhanced mucosal delivery of therapeutic compounds, United States
Patent Application, Pub. No.: US 2006/0062758 A1 (2006).
[105] K. Cui, S.-C. Chen Quay, K.T. Fry, Tight junction modulating peptides for enhanced
mucosal delivery of therapeutic compounds, United States Patent Application,
Pub. No.: US 2007/0154449 A1 (2007).
[106] A. Chandrasekaran, S. Sengupta, D.A. Berry, K. Holley, G. Zhao, R. Sasisekharan,
Methods and compositions related to the modulation of extracellular tight
junctions, United States Patent Application Publication, Pub. No.: US 2006/
0067927 A1 (2006).
[107] R.E. Herman, E.K. Makienko, M.G. Prieve, M. Fuller, M.E. Houston, P.H. Johnson,
Phage display screening of epithelial cell monolayers treated with EGTA:
identiﬁcation of peptide FDFWITP that modulates tight junction activity,
J. Biomol. Screen. 12 (2007) 1092–1101.
[108] T. Oshima, O. Blaschuk, B. Gour, M. Symonds, J.W. Elrod, M. Sasaki, T.H. Jackson,
J.S. Alexander, Tight junction peptide antagonists enhance neutrophil trans-
endothelial chemotaxis, Life Sci. 73 (2003) 1729–1740.
[109] A. Masuyama, M. Kondoh, H. Seguchi, A. Takahashi, M. Harada, M. Fujii, H.
Mizuguchi, Y. Horiguchi, Y. Watanabe, Role of N-terminal amino acids in the
absorption-enhancing effects of the c-terminal fragment of Clostridium perfrin-
gens enterotoxin, J. Pharmacol. Exp. Ther. 314 (2005) 789–795.
[110] A. Takahashi, M. Kondoh, A. Masuyama, M. Fujii, H. Mizuguchi, Y. Horiguchi, Y.
Watanabe, Role of C-terminal regions of the C-terminal fragment of Clostridium
perfringens enterotoxin in its interaction with claudin-4, J. Control. Release 108
(2005) 56–62.
[111] E. Sinaga, S.D.S. Jois, M. Avery, I.T. Makagiansar, U.S.F. Tambunan, K.L. Audus, T.J.
Siahaan, Increasing paracellular porosity by E-cadherin peptides: discovery of
bulge and groove regions in the EC1-domain of E-cadherin, Pharm. Res. 19
(2002) 1170–1179.
[112] N.D. Eddington, A. Fasano, K.-H. Song, Oral delivery of therapeutic agents using
tight junction agonists, United States Patent Application, Pub. No. US 2007/
0196272 A1 (2007).
[113] W. Wang, S. Uzzau, S.E. Goldblaum, A. Fasano, Human zonulin, a potential
modulator of intestinal tight junctions, J. Cell. Sci. 113 (2000) 4435–4440.
[114] I. Vietor, T. Bader, K. Paiha, L.A. Huber, Perturbation of the tight junction
permeability barrier by occludin loop peptides activates β-catenin/TCF/LEF-
mediated transcription, EMBO Reports 2 (2001) 306–312.
[115] N.N. Salama, A. Fasano, M. Thakar, N.D. Eddington, The impact of ΔG on the oral
bioavailability of low bioavailable therapeutic agents, J. Pharmacol. Exp. Ther. 312
(2005) 199–205.
[116] K.-H. Song, A. Fasano, N.D. Eddington, Effect of the six-mer synthetic peptide
908 M.A. Deli / Biochimica et Biophysica Acta 1788 (2009) 892–910(AT1002) fragment of zonula occludens toxin on the intestinal absorption of
cyclosporin A, Int. J. Pharm. 351 (2008) 8–14.
[117] M. Kondoh, A. Masuyama, A. Takahashi, N. Asano, H. Mizuguchi, N. Koizumi, M.
Fujii, T. Hayakawa, Y. Horiguchi, Y. Watanabe, A novel strategy for the
enhancement of drug absorption using a claudin modulator, Mol. Pharmacol.
67 (2005) 749–756.
[118] Z. Shao, Y. Li, T. Chermak, A.K. Mitra, Cyclodextrins as mucosal absorption
promoters of insulin. II. Effects of beta-cyclodextrin derivatives on alpha-
chymotryptic degradation and enteral absorption of insulin in rats, Pharm. Res.
11 (1994) 1174–1179.
[119] A. Yamamoto, H. Tatsumi, M. Maruyama, T. Uchiyama, N. Okada, T. Fujita,
Modulation of intestinal permeability by nitric oxide donors: implications in
intestinal delivery of poorly absorbable drugs, J. Pharmacol. Exp. Ther. 296
(2001) 84–90.
[120] G. Fetih, F. Habib, N. Okada, T. Fujita, M. Attia, A. Yamamoto, Nitric oxide donors
can enhance the intestinal transport and absorption of insulin and [Asu(1,7)]-eel
calcitonin in rats, J. Control. Release 106 (2005) 287–297.
[121] G. Fetih, F. Habib, H. Katsumi, N. Okada, T. Fujita, M. Attia, A. Yamamoto, Excellent
absorption enhancing characteristics of NO donors for improving the intestinal
absorption of poorly absorbable compound compared with conventional
absorption enhancers, Drug Metab. Pharmacokinet. 21 (2006) 222–229.
[122] J.D. Söderholm, H. Oman, L. Blomquist, J. Veen, T. Lindmark, G. Olaison,
Reversible increase in tight junction permeability to macromolecules in rat ileal
mucosa by sodium caprate, a constituent of milk fat, Dig. Dis. Sci. 43 (1998)
1547–1552.
[123] D. Cox, H. Gao, S. Raje, K. Scott, N.D. Eddington, Enhancing the permeation of
marker compounds and emaninone anticonvulsants across Caco-2 monolayers
by modulating tight junctions using zonula occludens toxin, Eur. J. Pharm.
Biopharm. 52 (2001) 145–150.
[124] D. Cox, S. Raje, H. Gao, N.N. Salama, N.D. Eddington, Enhanced permeability of
molecular weight markers and poorly bioavailable compounds across Caco-2
monolayers using the absorption enhancer, zonula occludens toxin, Pharm. Res.
19 (2002) 1680–1688.
[125] M. Tomita, M. Hayashi, S. Awazu, Comparison of absorption-enhancing effect
between sodium caprate and disodium ethylenediaminetetraacetate in Caco-2
cells, Biol. Pharm. Bull. 17 (1994) 753–755.
[126] Y.S. Quan, T. Fujita, F. Kamiyama, A. Yamamoto, Electrophysiological studies on
the evaluation of absorption enhancers in Caco-2 cells using a microelectrode
technique, Biol. Pharm. Bull. 23 (2000) 738–742.
[127] T. Sawai, R.A. Drongowski, R.W. Lampman, A.G. Coran, C.M. Harmon, The effect of
phospholipids and fatty acids on tight-junction permeability and bacterial
translocation, Pediatr. Surg. Int. 17 (2001) 269–274.
[128] B. Aspenström-Fagerlund, L. Ring, P. Aspenström, J. Tallkvist, N.G. Ilbäck, A.W.
Glynn, Oleic acid and docosahexaenoic acid cause an increase in the paracellular
absorption of hydrophilic compounds in an experimental model of human
absorptive enterocytes, Toxicology 237 (2007) 12–23.
[129] T. Lindmark, T. Nikkilä, P. Artursson, Mechanisms of absorption enhancement by
medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers, J.
Pharmacol. Exp. Ther. 275 (1995) 958–964.
[130] T. Lindmark, Y. Kimura, P. Artursson, Absorption enhancement through
intracellular regulation of tight junction permeability by medium chain fatty
acids in Caco-2 cells, J. Pharmacol. Exp. Ther. 284 (1998) 362–369.
[131] E.L. Lecluyse, S.C. Sutton, J.A. Fix, In vitro effects of long-chain acylcarnitines on
the permeability, transepithelial electrical resistance and morphology of rat
colonic mucosa, J. Pharmacol. Exp. Ther. 265 (1993) 955–962.
[132] J.H. Hochman, J.A. Fix, E.L. LeCluyse, In vitro and in vivo analysis of the
mechanism of absorption enhancement by palmitoylcarnitine, J. Pharmacol. Exp.
Ther. 269 (1994) 813–822.
[133] E.K. Anderberg, C. Nyström, P. Artursson, Epithelial transport of drugs in cell
culture. VII: Effects of pharmaceutical surfactant excipients and bile acids
on transepithelial permeability in monolayers of human intestinal epithelial
(Caco-2) cells, J. Pharm. Sci. 81 (1992) 79–87.
[134] E.K. Anderberg, T. Lindmark, P. Artursson, Sodium caprate elicits dilatations in
human intestinal tight junctions and enhances drug absorption by the
paracellular route, Pharm. Res. 10 (1993) 857–864.
[135] D. Dimitrijevic, A.J. Shaw, A.T. Florence, Effects of some non-ionic surfactants on
transepithelial permeability in Caco-2 cells, J. Pharm. Pharmacol. 52 (2000)
157–162.
[136] M.H. Doo, H. Li, H.I. Jang, I.S. Song, S.J. Chung, C.K. Shim, Effect of nonylphenol
ethoxylates (NPEs) on barrier functions of epithelial cell membranes: opening of
tight junctions and competitive inhibition of P-gp-mediated efﬂux, Int. J. Pharm.
302 (2005) 145–153.
[137] G. Ranaldi, I. Marigliano, I. Vespignani, G. Perozzi, Y. Sambuy, The effect of
chitosan and other polycations on tight junction permeability in the human
intestinal Caco-2 cell line, J. Nutr. Biochem 13 (2002) 157–167.
[138] J.M. Smith, M. Dornish, E.J. Wood, Involvement of protein kinase C in chitosan
glutamate-mediated tight junctiondisruption, Biomaterials 26 (2005) 3269–3276.
[139] M. Marinaro, A. Fasano, M.T. De Magistris, Zonula occludens toxin acts as an
adjuvant through different mucosal routes and induces protective immune
responses, Infect. Immun. 71 (2003) 1897–1902.
[140] T. Lindmark, J.D. Söderholm, G. Olaison, G. Alván, G. Ocklind, P. Artursson,
Mechanisms of absorption enhancement in humans after rectal administration
of ampicillin in suppositories containing sodium caprate, Pharm. Res. 14 (1997)
930–935.
[141] Y. Watanabe, Y. Matsumoto, M. Seki, M. Takase, M. Matsumoto, Absorption
enhancement of polypeptide drugs by cyclodextrins. I. Enhanced rectalabsorption of insulin from hollow-type suppositories containing insulin and
cyclodextrins in rabbits, Chem. Pharm. Bull. (Tokyo) 40 (1992) 3042–3047.
[142] N. Utoguchi, Y. Watanabe, T. Shida, M. Matsumoto, Nitric oxide donors enhance
rectal absorption of macromolecules in rabbits, Pharm. Res. 15 (1998) 870–876.
[143] M. Rossi, F. Maurano, D. Luongo, A. Fasano, S. Uzzau, S. Auricchio, R. Troncone,
Zonula occludens toxin (Zot) interferes with the induction of nasal tolerance to
gliadin, Immunol. Lett. 81 (2002) 217–221.
[144] K.-H. Song, A. Fasano, N.D. Eddington, Enhanced nasal absorption of hydrophilic
markers after dosing with AT1002, a tight junction modulator, Eur. J. Pharm.
Biopharm. 69 (2008) 231–237.
[145] S.C. Chen, K. Eiting, K. Cui, A.K. Leonard, D. Morris, C.Y. Li, K. Farber, A.P. Sileno,
M.E. Houston, P.H. Johnson, S.C. Quay, H.R. Constantino, Therapeutic utility of a
novel tight junction modulating peptide for enhancing intranasal drug delivery,
J. Pharm. Sci. 95 (2006) 1364–1371.
[146] G. Wang, J. Zabner, C. Deering, J. Launspach, J. Shao, M. Bodner, D.J. Jolly, B.L.
Davidson, P.B. McCray, Increasing epithelial junction permeability enhances gene
transfer to airway epithelia in vivo, Am. J. Respir. Cell Mol. Biol. 22 (2000) 129–138.
[147] H. Lin, M. Gebhardt, S. Bian, K.A. Kwon, C.K. Shim, S.J. Chung, D.D. Kim, Enhancing
effect of surfactants on fexofenadine.HCl transport across the human nasal
epithelial cell monolayer, Int. J. Pharm. 330 (2007) 23–31.
[148] Y. Watanabe, Y. Matsumoto, K. Kawamoto, S. Yazawa, M. Matsumoto, Enhancing
effect of cyclodextrins on nasal absorption of insulin and its duration in rabbits,
Chem. Pharm. Bull. (Tokyo) 40 (1992) 3100–3104.
[149] T. Yang, A. Hussain, J. Paulson, T.J. Abbruscato, F. Ahsan, Cyclodextrins in nasal
delivery of low-molecular-weight heparins: in vivo and in vitro studies, Pharm.
Res. 21 (2004) 1127–1136.
[150] C.A. Herbert, C.M. King, P.C. Ring, S.T. Holgate, G.A. Stewart, P.J. Thompson, C.
Robinson, Augmentation of permeability in the bronchial epithelium by the
house dust mite allergen Der p1, Am. J. Respir. Cell Mol. Biol. 12 (1995) 369–378.
[151] C.B. Coyne, M.M. Kelly, R.C. Boucher, L.G. Johnson, Enhanced epithelial gene
transfer by modulation of tight junctions with sodium caprate, Am. J. Respir. Cell
Mol. Biol. 23 (2000) 602–609.
[152] L.Y. Wang, J.K. Ma, W.F. Pan, D. Toledo-Velasquez, C.J. Malanga, Y. Rojanasakul,
Alveolar permeability enhancement by oleic acid and related fatty acids:
evidence for a calcium-dependent mechanism, Pharm. Res. 11 (1994) 513–517.
[153] K. Morita, H. Sasaki, M. Furuse, S. Tsukita, Endothelial claudin: claudin-5/TMVCF
constitutes tight junction strands in endothelial cells, J. Cell Biol. 147 (1999)
185–194.
[154] K. Fujita, J. Katahira, Y. Horiguchi, N. Sonoda, M. Furuse, S. Tsukita, Clostridium
perfringens enterotoxin binds to the second extracellular loop of claudin-3, a
tight junction integral membrane protein, FEBS Lett. 476 (2000) 258–261.
[155] R. Lu, W. Wang, S. Uzzau, R. Vigorito, H.R. Zielke, A. Fasano, Afﬁnity puriﬁcation
and partial characterization of the zonulin/zonula occludens toxin (Zot)
receptor from human brain, J. Neurochem. 74 (2000) 320–326.
[156] N.N. Salama, N.D. Eddington, A. Fasano, Tight junction modulation and its
relationship to drug delivery, Adv. Drug Deliv. Rev. 58 (2006) 15–28.
[157] W.L. Wang, R.L. Lu, M. DiPierro, A. Fasano, Zonula occludin toxin, a microtubule
binding protein, World J. Gastroenterol. 6 (2000) 330–334.
[158] C.S. Karyekar, A. Fasano, S. Raje, R. Lu, T.C. Dowling, N.D. Eddington, Zonula
occludens toxin increases the permeability of molecular weight markers and
chemotherapeutic agents across the bovine brain microvessel endothelial cells,
J. Pharm. Sci. 92 (2003) 414–423.
[159] M. Tomita, M. Hayashi, S. Awazu, Absorption-enhancing mechanism of EDTA,
caprate, and decanoylcarnitine in Caco-2 cells, J. Pharm. Sci. 85 (1996) 608–611.
[160] R. Notman, M.G. Noro, J. Anwar, Interaction of oleic acid with dipalmitoylphos-
phatidylcholine (DPPC) bilayers simulated by molecular dynamics, J. Phys.
Chem. B. 111 (2007) 12748–12755.
[161] J.Y. Park, Y.M. Kim, H.S. Song, K.Y. Park, Y.M. Kim, M.S. Kim, Y.K. Pak, I.K. Lee, J.D.
Lee, S.J. Park, K.U. Lee, Oleic acid induces endothelin-1 expression through
activation of protein kinase C and NF-kappa B, Biochem. Biophys. Res. Commun.
303 (2003) 891–895.
[162] S.Y. Oh, B.V. Madhukar, J.E. Trosko, Inhibition of gap junctional blockage by
palmitoyl carnitine and TMB-8 in a rat liver epithelial cell line, Carcinogenesis 9
(1988) 135–139.
[163] C. Schulze, C. Smales, L.L. Rubin, J.M. Staddon, Lysophosphatidic acid increases
tight junction permeability in cultured brain endothelial cells, J. Neurochem. 68
(1997) 991–1000.
[164] T. Chiu, E. Rozengurt, PKD in intestinal epithelial cells: rapid activation by
phorbol esters, LPA, and angiotensin through PKC, Am. J. Physiol. Cell. Physiol.
280 (2001) C929–C942.
[165] K.P. Xu, X.F. Li, F.S. Yu, Corneal organ culture model for assessing epithelial
responses to surfactants, Toxicol. Sci. 58 (2000) 306–314.
[166] K. Dharmsathaphorn, P.A. Huott, P. Vongkovit, G. Beuerlein, S.J. Pandol, H.V.
Ammon, Cl− secretion induced by bile salts. A study of the mechanism of action
based on a cultured colonic epithelial cell line, J. Clin. Invest. 84 (1989) 945–953.
[167] Z. Nagy, H. Peters, I. Hüttner, Charge-related alterations of the cerebral
endothelium, Lab. Invest. 49 (1983) 662–671.
[168] E.B. Peixoto, C.B. Collares-Buzato, Protamine-induced epithelial barrier disrup-
tion involves rearrangement of cytoskeleton and decreased tight junction-
associated protein expression in cultured MDCK strains, Cell Struct. Funct. 29
(2005) 165–178.
[169] S. Vepa, W.M. Scribner, V. Natarajan, Activation of endothelial cell phospholipase
D by polycations, Am. J. Physiol. 272 (1997) L608–L613.
[170] N.G. Schipper, S. Olsson, J.A. Hoogstraate, A.G. de Boer, K.M. Vårum, P. Artursson,
Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of
absorption enhancement, Pharm. Res. 14 (1997) 923–929.
909M.A. Deli / Biochimica et Biophysica Acta 1788 (2009) 892–910[171] V. Dodane, M. Amin Khan, J.R. Merwin, Effect of chitosan on epithelial
permeability and structure, Int. J. Pharm. 182 (1999) 21–32.
[172] V. Monnaert, D. Betbeder, L. Fenart, H. Bricout, A.M. Lenfant, C. Landry, R.
Cecchelli, E. Monﬂier, S. Tilloy, Effects of gamma- and hydroxypropyl-gamma-
cyclodextrins on the transport of doxorubicin across an in vitro model of blood–
brain barrier, J. Pharmacol. Exp. Ther. 311 (2004) 1115–1120.
[173] V. Monnaert, S. Tilloy, H. Bricout, L. Fenart, R. Cecchelli, E. Monﬂier, Behavior of
alpha-, beta-, and gamma-cyclodextrins and their derivatives on an in vitro
model of blood–brain barrier, J. Pharmacol. Exp. Ther. 310 (2004) 745–751.
[174] N.S. Ningaraj, M. Rao, K. Hashizume, K. Asotra, K.L. Black, Regulation of blood–
brain tumor barrier permeability by calcium-activated potassium channels,
J. Pharmacol. Exp. Ther. 301 (2002) 838–851.
[175] A. Farkas, E. Szatmári, A. Orbók, I. Wilhelm, K. Wejksza, P. Nagyőszi, P.
Hutamekalin, H. Bauer, H.-C. Bauer, A. Traweger, I.A. Krizbai, Hyperosmotic
mannitol induces Src kinase-dependent phosphorylation of beta-catenin in
cerebral endothelial cells, J. Neurosci. Res. 80 (2005) 855–861.
[176] S.B. Raymond, J. Skoch, K. Hynynen, B.J. Bacskai, Multiphoton imaging of
ultrasound/Optison mediated cerebrovascular effects in vivo, J. Cereb. Blood
Flow Metab. 27 (2007) 393–403.
[177] J.A. Nicolazzo, B.L. Reed, B. Finnin, Buccal penetration enhancers — how do they
really work? J. Control. Release 105 (2005) 1–15.
[178] Y.S. Quan, K. Hattori, E. Lundborg, T. Fujita, M. Murakami, S. Muranishi, A.
Yamamoto, Effectiveness and toxicity screening of various absorption enhancers
using Caco-2 cell monolayers, Biol. Pharm. Bull. 21 (1998) 615–620.
[179] A. Kogan, N. Garti, Microemulsions as transdermal drug delivery vehicles, Adv.
Colloid Interface Sci. 123–126 (2006) 369–385.
[180] A. Melero, T.M. Garrigues, P. Almudever, A.M. Villodre, C.M. Lehr, U. Schäfer,
Nortriptyline hydrochloride skin absorption: development of a transdermal
patch, Eur. J. Pharm. Biopharm. 69 (2008) 588–596.
[181] L. Sztriha, A.L. Betz, Oleic acid reversibly opens the blood–brain barrier, Brain Res.
550 (1991) 257–262.
[182] H.J. Kim, Y.S. Pyeun, Y.W. Kim, B.M. Cho, T.H. Lee, T.Y. Moon, K.T. Suh, B.R. Park,
A model for research on the blood–brain barrier disruption induced by
unsaturated fatty acid emulsion, Invest. Radiol. 40 (2005) 270–276.
[183] T. Lindmark, N. Schipper, L. Lazorová, A.G. de Boer, P. Artursson, Absorption
enhancement in intestinal epithelial Caco-2 cell monolayers by sodium caprate:
assessment of molecular weight dependence and demonstration of transport
routes, J. Drug Target. 5 (1998) 215–223.
[184] E. Duizer, C. van der Wulp, C.H. Versantvoort, J.P. Groten, Absorption
enhancement, structural changes in tight junctions and cytotoxicity caused
by palmitoyl carnitine in Caco-2 and IEC-18 cells, J. Pharmacol. Exp. Ther. 287
(1998) 395–402.
[185] R.G. Strickley, Solubilizing excipients in oral and injectable formulations, Pharm.
Res. 21 (2004) 201–230.
[186] S.S. Davis, L. Illum, Absorption enhancers for nasal drug delivery, Clin.
Pharmacokinet. 42 (2003) 1107–1128.
[187] M. Suzuki, M. Machida, K. Adachi, K. Otabe, T. Sugimoto, M. Hayashi, S. Awazu,
Histopathological study of the effects of a single intratracheal instillation of
surface active agents on lung in rats, J. Toxicol. Sci. 25 (2000) 49–55.
[188] G.T.A. McEwan, M.A. Jepson, B.H. Hirst, N.L. Simmons, Polycation-induced
enhancement of epithelial paracellular permeability is independent of tight
junctional characteristics, Biochim. Biophys. Acta 1148 (1993) 51–60.
[189] X.Y. Yu, B.H. Schoﬁeld, T. Croxton, N. Takahashi, E.W. Gabrielson, E.W. Spannhake,
Physiologic modulation of bronchial epithelial cell barrier function by poly-
cationic exposure, Am. J. Respir. Cell Mol. Biol. 11 (1994) 188–198.
[190] C. Valenta, B.G. Auner, The use of polymers for dermal and transdermal delivery,
Eur. J. Pharm. Biopharm. 58 (2004) 279–289.
[191] M. Thanou, J.C. Verhoef, H.E. Junginger, Oral drug absorption enhancement by
chitosan and its derivatives, Adv. Drug Deliv. Rev. 52 (2001) 117–126.
[192] H.O. Alpar, S. Somavarapu, K.N. Atuah, V.W. Bramwell, Biodegradable muco-
adhesive particulates for nasal and pulmonary antigen and DNA delivery, Adv.
Drug Deliv. Rev. 57 (2005) 411–430.
[193] J.M. Smith, E.J. Wood, M. Dornish, Effect of chitosan on epithelial cell tight
junctions, Pharm. Res. 21 (2004) 43–49.
[194] T. Loftsson, S.B. Vogensen, M.E. Brewster, F. Konrádsdóttir, Effects of cyclodex-
trins on drug delivery through biological membranes, J. Pharm. Sci. 96 (2007)
2532–2546.
[195] F.W. Merkus, J.C. Verhoef, S.G. Romeijn, N.G. Schipper, Absorption enhancing
effect of cyclodextrins on intranasally administered insulin in rats, Pharm. Res. 8
(1991) 588–592.
[196] T. Kiss, F. Fenyvesi, B.I. Kovácsné, P. Fehér, K.R. Leposáné, J. Váradi, L. Szente, E.
Fenyvesi, R. Iványi, M. Vecsernyés, Cytotoxic examinations of various cyclodex-
trin derivatives on Caco-2 cells, Acta Pharm. Hung. 77 (2007) 150–154.
[197] L. Matilainen, T. Toropainen, H. Vihola, J. Hirvonen, T. Järvinen, P. Jarho, K.
Järvinen, In vitro toxicity and permeation of cyclodextrins in Calu-3 cells,
J. Control. Release 126 (2008) 10–16.
[198] M.P. Fink, R.L. Delude, Epithelial barrier dysfunction: a unifying theme to explain
the pathogenesis of multiple organ dysfunction at the cellular level, Crit. Care
Clin. 21 (2005) 177–196.
[199] X. Han, M.P. Fink, R. Yang, R.L. Delude, Increased iNOS activity is essential for
intestinal epithelial tight junction dysfunction in endotoxemic mice, Shock 21
(2004) 261–270.
[200] N. Numata, K. Takahashi, N. Mizuno, N. Utoguchi, Y. Watanabe, M. Matsumoto, T.
Mayumi, Improvement of intestinal absorption of macromolecules by nitric
oxide donor, J. Pharm. Sci. 89 (2000) 1296–1304.
[201] Y. Watanabe, N. Utoguchi, A. Ishii, Y. Tai, H. Shiota, H. Kurai, M. Matsumoto,Absorption enhancement of a protein drug by nitric oxide donor: effect on nasal
absorption of human granulocyte colony-stimulating factor, J. Drug Target. 8
(2000) 185–194.
[202] K. Takahashi, N. Numata, N. Kinoshita, N. Utoguchi, T. Mayumi, N. Mizuno,
Characterization of the inﬂuence of nitric oxide donors on intestinal absorption
of macromolecules, Int. J. Pharm. 286 (2004) 89–97.
[203] D. Menon, C.S. Karyekar, A. Fasano, R. Lu, N.D. Eddington, Enhancement of brain
distribution of anticancer agents usingΔG, the 12 kDa active fragment of ZOT, Int.
J. Pharm. 306 (2005) 122–131.
[204] K. Nagasawa, H. Chiba, H. Fujita, T. Kojima, T. Saito, T. Endo, N. Sawada, Possible
ninvolvement of gap junctions in the barrier function of tight junctions of brain
and lung endothelial cells, J. Cell. Physiol. 208 (2006) 123–132.
[205] D.F. Emerich, P. Snodgrass, M. Pink, F. Bloom, R.T. Bartus, Central analgesic actions
of loperamide following transient permeation of the blood–brain barrier with
Cereport (RMP-7), Brain Res. 801 (1998) 252–266.
[206] C.V. Borlongan, D.F. Emerich, B.J. Hoffer, R.T. Bartus, Bradykinin receptor agonist
facilitates low-dose cyclosporin-A protection against 6-hydroxydopamine
neurotoxicity, Brain Res. 956 (2002) 211–220.
[207] C.V. Borlongan, D.F. Emerich, Facilitation of drug entry into the CNS via
transient permeation of blood–brain barrier: laboratory and preliminary
clinical evidence from bradykinin receptor agonist, Cereport, Brain Res. Bull.
60 (2003) 297–306.
[208] D.F. Emerich, R.L. Dean, C. Osborn, R.T. Bartus, The development of the bradykinin
agonist labradimil as ameans to increase thepermeability of the blood–brainbarrier:
from concept to clinical evaluation, Clin. Pharmacokinet. 40 (2001) 105–123.
[209] K. Warren, R. Jalacki, B. Widemann, A. Aikin, M. Libucha, R. Packer, G. Vezina, G.
Reaman, D. Shaw, M. Krailo, C. Osborne, J. Cehelsky, D. Caldwell, J. Stanwood, S.M.
Steinberg, F.M. Balis, Phase II trial of intravenous lobradimil and carboplatin in
childhood brain tumors: a report from the Children's Oncology Group, Cancer
Chemother. Pharmacol. 58 (2006) 343–347.
[210] T. Nomura, K. Ikezaki, K. Matsukado, M. Fukui, Effect of histamine on the blood-
tumor barrier in transplanted rat brain tumors, Acta Neurochir. Suppl. (Wien) 60
(1994) 400–402.
[211] T. Inamura, T. Nomura, K. Ikezaki, M. Fukui, G. Pöllinger, K.L. Black, Intracarotid
histamine infusion increases blood tumour permeability in RG2 glioma, Neurol.
Res. 16 (1994) 125–128.
[212] T.J. Raub, S.L. Kuentzel, G.A. Sawada, Permeability of bovine brain microvessel
endothelial cells in vitro: barrier tightening by a factor released from astroglioma
cells, Exp. Cell Res. 199 (1992) 330–340.
[213] E. Preston, J. Slinn, I. Vinokourov, D. Stanimirovic, Graded reversible opening of
the rat blood–brain barrier by intracarotid infusion of sodium caprate, J.
Neurosci. Methods 168 (2008) 443–449.
[214] A. Saija, P. Princi, D. Trombetta, M. Lanza, A. De Pasquale, Changes in the
permeability of the blood–brain barrier following sodium dodecyl sulphate
administration in the rat, Exp. Brain Res. 115 (1997) 546–551.
[215] M.K. Spigelman, R.A. Zappulla, L.I. Malis, J.F. Holland, S.J. Goldsmith, J.D.
Goldberg, Intracarotid dehydrocholate infusion: a new method for prolonged
reversible blood–brain barrier disruption, Neurosurgery 12 (1983) 606–612.
[216] R.A. Zappulla, M.K. Spigelman, E. Omsberg, J.J. Rosen, L.I. Malis, J.F. Holland,
Electroencephalographic consequences of sodium dehydrocholate-induced
blood–brain barrier disruption: Part 1. Acute and chronic effects of intracarotid
sodium dehydrocholate, Neurosurgery 16 (1985) 630–638.
[217] J. Greenwood, J. Adu, A.J. Davey, N.J. Abbott, M.W.B. Bradbury, The effect of bile
salts on the permeability and ultrastructure of the perfused, energy-depleted, rat
blood–brain barrier, J. Cereb. Blood Flow Metab. 11 (1991) 644–654.
[218] M. Mikov, S. Kevresan, K. Kuhajda, V. Jakovljević, V. Vasović, 3-Alpha,7-alpha-
dihydroxy-12-oxo-5beta-cholanate as blood–brain barrier permeator, Pol. J.
Pharmacol. 56 (2004) 367–371.
[219] I. Westergren, B.B. Johansson, Altering the blood–brain barrier in the rat by
intracarotid infusion of polycations: a comparison between protamine, poly-L-
lysine and poly-L-arginine, Acta Physiol. Scand. 149 (1993) 99–104.
[220] J. Yao, J.P. Zhou, Q.N. Ping, Y. Lu, L. Chen, Distribution of nobiletin chitosan-based
microemulsions in brain following i.v. injection in mice, Int. J. Pharm. 352 (2008)
256–262.
[221] S. Tilloy, V. Monnaert, L. Fenart, H. Bricout, R. Cecchelli, E. Monﬂier, Methylated
beta-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in
vitro model of blood–brain barrier, Bioorg. Med. Chem. Lett. 16 (2006)
2154–2157.
[222] K.M. Boje, S.S. Lakhman, Nitric oxide redox species exert differential
permeability effects on the blood–brain barrier, J. Pharmacol. Exp. Ther. 293
(2000) 545–550.
[223] M.-P. Dehouck, S. Méresse, P. Delorme, J.C. Fruchart, R. Cecchelli, An easier,
reproducible, and mass-production method to study the blood–brain barrier in
vitro, J. Neurochem. 54 (1990) 1798–1801.
[224] D.H. Dobrogowska, A.W. Vorbrodt, Immunogold localization of tight junctional
proteins in normal and osmotically-affected rat blood–brain barrier, J. Mol.
Histol. 35 (2004) 529–539.
[225] M.A. Deli, L. Descamps, M.-P. Dehouck, R. Cecchelli, F. Joó, C.S. Ábrahám, G.
Torpier, Exposure of tumor necrosis factor α to the luminal membrane induces a
delayed increase of permeability and formation of cytoplasmic actin stress ﬁbers
in brain capillary endothelial cells cocultured with astrocytes, J. Neurosci. Res. 41
(1995) 717–726.
[226] L.L. Muldoon, C. Soussain, K. Jahnke, C. Johanson, T. Siegal, Q.R. Smith, W.A. Hall,
K. Hynynen, P.D. Senter, D.M. Peereboom, E.A. Neuwelt, Chemotherapy delivery
issues in central nervous system malignancy: a reality check, J. Clin. Oncol. 25
(2007) 2295–2305.
910 M.A. Deli / Biochimica et Biophysica Acta 1788 (2009) 892–910[227] B. Erdlenbruch, C. Schinkhof, W. Kugler, D.E.H. Heinemann, J. Herms, H. Eibl, M.
Lakomek, Intracarotid administration of short-chain alkylglycerols for increased
delivery of methotrexate to the brain, Br. J. Pharmacol. 139 (2003) 685–694.
[228] B. Erdlenbruch, M. Alipour, G. Fricker, D.S. Miller, W. Kugler, H. Eibl, M. Lakomek,
Alkylglycerol opening of the blood–brain barrier to small and large ﬂuorescence
markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries,
Br. J. Pharmacol. 140 (2003) 1201–1210.
[229] K. Hynynen, N. McDannold, N. Vykhodtseva, S. Raymond, R. Weissleder, F.A.
Jolesz, N. Sheikov, Focal disruption of the blood–brain barrier due to 260-kHz
ultrasound bursts: a method for molecular imaging and targeted drug delivery,
J. Neurosurg. 105 (2006) 445–454.
[230] M. Kinoshita, N. McDannold, F. Jolesz, K. Hynynen, Targeted delivery of
antibodies through the blood–brain barrier by MRI-guided focused ultrasound,
Biochem. Biophys. Res. Commun. 340 (2006) 1085–1090.
[231] M. Kinoshita, N. McDannold, F.A. Jolesz, K. Hynynen, Noninvasive localized
delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-
induced blood–brain barrier disruption, Proc. Natl. Acad. Sci. U. S. A. 103 (2006)
11719–11723.
[232] L.H. Treat, N. McDannold, N. Vykhodtseva, Y. Zhang, K. Tam, K. Hynynen, Targeted
delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided
focused ultrasound, Int. J. Cancer 121 (2007) 901–907.
[233] M.J. Williams, M.B. Lowrie, J.P. Bennett, J.A. Firth, P. Clark, Cadherin-10 is a novel
blood–brain barrier adhesion molecule in human and mouse, Brain Res. 1058
(2005) 62–72.
[234] B.J. Gentil, C. Benaud, C. Delphin, C. Remy, V. Berezowski, R. Cecchelli, O. Feraud,
D. Vittet, J. Baudier, Speciﬁc AHNAK expression in brain endothelial cells with
barrier properties, J. Cell. Physiol. (2004) 133–144.
[235] F. Joó, The role of histamine in brain oedema formation, Funct. Neurology 8
(1993) 243–250.
[236] T.F. Cloughesy, K.L. Black, Pharmacological blood–brain barrier modiﬁcation for
selective drug delivery, J. Neurooncol. 26 (1995) 125–132.
[237] P. Vajkoczy, M.D. Menger, Vascular microenvironment in gliomas, Cancer Treat.
Res. 117 (2004) 249–262.
[238] H. Ishihara, H. Kubota, R.L. Lindbergh, D. Leppert, S.M. Gloor, M. Errede, D.
Virgintino, A. Fontana, Y. Yonekawa, K. Frei, Endothelial cell barrier impairment
induced by glioblastomas and transforming growth factor beta2 involves matrix
metalloproteinases and tight junction proteins, J. Neuropathol. Exp. Neurol. 67
(2008) 435–448.
[239] S.R. Doctrow, S.M. Abelleira, L.A. Curry, R. Heller-Harrison, J.W. Kozarich, B.
Malfroy, L.A. McCarroll, K.G. Morgan, A.R. Morrow, G.F. Musso, The bradykinin
analog RMP-7 increases intracellular free calcium levels in rat brain
microvascular endothelial cells, J. Pharmacol. Exp. Ther. 271 (1994) 229–237.
[240] E. Sanovich, R.T. Bartus, P.M. Friden, R.L. Dean, H.Q. Lea, M.W. Brightman,
Pathway across blood–brain barrier opened by the bradykinin agonist, RMP-7,
Brain Res. 705 (1995) 125–135.
[241] X. Zhang, Y. Xie, Y. Jin, X. Hou, L. Ye, J. Lou, The effect of RMP-7 and its derivative
on transporting Evans blue liposomes into the brain, Drug Deliv. 11 (2004)
301–309.
[242] M.H. Sarker, P.A. Fraser, The role of guanylyl cyclases in the permeability response
to inﬂammatory mediators in pial venular capillaries in the rat, J. Physiol. 540
(2002) 209–218.
[243] A. Yamauchi, S. Dohgu, T. Nishioku, H. Shuto, M. Naito, T. Tsuruo, Y. Sawada, Y.
Kataoka, An inhibitory role of nitric oxide in the dynamic regulation of the
blood–brain barrier function, Cell. Mol. Neurobiol. 27 (2007) 263–270.
[244] T.W. Gardner, T. Lesher, S. Khin, C. Vu, A.J. Barber, W.A. Brennan Jr., Histaminereduces ZO-1 tight-junction protein expression in cultured retinal microvascular
endothelial cells, Biochem. J. 320 (1996) 717–721.
[245] T. Nitz, T. Eisenblatter, K. Psathaki, H.J. Galla, Serum-derived factors weaken the
barrier properties of cultured porcine brain capillary endothelial cells in vitro,
Brain Res. 981 (2003) 30–40.
[246] R.A. Zappulla, M.K. Spigelman, J.J. Rosen, D. Marotta, L.I. Malis, J.F. Holland,
Electroencephalographic consequences of sodium dehydrocholate-induced
blood–brain barrier disruption: Part 2. Generation and propagation of spike
activity after the topical application of sodium dehydrocholate, Neurosurgery 16
(1985) 639–643.
[247] O. Tomkins, O. Friedman, S. Ivens, C. Reiffurth, S. Major, J.P. Dreier, U. Heinemann,
A. Friedman, Blood–brain barrier disruption results in delayed functional and
structural alterations in the rat neocortex, Neurobiol. Dis. 25 (2007) 367–377.
[248] S.I. Rapoport, Advances in osmotic opening of the blood–brain barrier to enhance
CNS chemotherapy, Expert Opin. Investig. Drugs 10 (2001) 1809–1818.
[249] B. Erdlenbruch, V. Jendrossek, H. Eibl, M. Lakomek, Transient and controllable
opening of the blood–brain barrier to cytostatic and antibiotic agents by
alkylglycerols in rats, Exp. Brain Res. 135 (2000) 417–422.
[250] B. Erdlenbruch, V. Jendrossek, W. Kugler, H. Eibl, M. Lakomek, Increased delivery
of erucylphosphocholine to C6 gliomas by chemical opening of the blood–brain
barrier using intracarotid pentylglycerol in rats, Cancer Chemother. Pharmacol.
50 (2002) 299–304.
[251] M. Kinoshita, Targeted drug delivery to the brain using focused ultrasound, Top.
Magn. Reson. Imaging 17 (2006) 209–215.
[252] N. Sheikov, N. McDannold, N. Vykhodtseva, F. Jolesz, K. Hynynen, Cellular
mechanisms of the blood–brain barrier opening induced by ultrasound in
presence of microbubbles, Ultrasound Med. Biol. 30 (2004) 979–989.
[253] N. Strazielle, S.T. Khuth, J.F. Ghersi-Egea, Detoxiﬁcation systems, passive and
speciﬁc transport for drugs at the blood-CSF barrier in normal and pathological
situations, Adv. Drug Deliv. Rev. 56 (2004) 1717–1740.
[254] C.E. Johanson, J.A. Duncan, E.G. Stopa, A. Baird, Enhanced prospects for drug
delivery and brain targeting by the choroid plexus-CSF route, Pharm. Res. 22
(2005) 1011–1037.
[255] A. Lippoldt, S. Liebner, B. Andbjer, H. Kalbacher, H. Wolburg, H. Haller, K. Fuxe,
Organization of choroid plexus epithelial and endothelial cell tight junctions and
regulation of claudin-1, -2 and -5 expression by protein kinase C, Neuroreport 11
(2000) 1427–1431.
[256] H. Wolburg, K. Wolburg-Buchholz, S. Liebner, B. Engelhardt, Claudin-1, claudin-2
and claudin-11 are present in tight junctions of choroid plexus epithelium of the
mouse, Neurosci. Lett. 307 (2001) 77–80.
[257] M. Haselbach, J. Wegener, S. Decker, C. Engelbertz, H.J. Galla, Porcine choroid
plexus epithelial cells in culture: regulation of barrier properties and transport
processes, Microsc. Res. Tech. 52 (2001) 137–152.
[258] A. Lippoldt, A. Jansson, U. Kniesel, B. Andbjer, A. Andersson, H. Wolburg, K. Fuxe,
H. Haller, Phorbol ester induced changes in tight and adherens junctions in the
choroid plexus epithelium and in the ependyma, Brain Res. 854 (2000) 197–206.
[259] S. Angelow, P. Zeni, B. Höhn, H.J. Galla, Phorbol ester induced short- and long-
term permeabilization of the blood-CSF barrier in vitro, Brain Res. 1063 (2005)
168–179.
[260] References for clinical trials investigating the safety and efﬁcacy of AT-1001 can
be found at http://www.clinicaltrials.gov (NCT00386165, NCT00386490,
NCT00492960, NCT00620451).
[261] References for clinical trials investigating the safety and efﬁcacy of PN-159 can be
found at http://www.clinicaltrials.gov (NCT00362856, NCT00537420,
NCT00624767).
